[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fCKJsJl4SUZktmEV6Fpvdo64ItWabpwOw7DhQWLK2TUM":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":33,"phaseBuckets":82,"rows":89},"Shanghai Junshi Bioscience Co., Ltd.",[4],97,false,29,25,21016,58,0,[14,17,20,22,24,26,28,31],{"name":15,"count":16},"Hyperlipemia",4,{"name":18,"count":19},"Advanced Hepatocellular Carcinoma (HCC)",3,{"name":21,"count":19},"NSCLC",{"name":23,"count":19},"Advanced Lung Cancer",{"name":25,"count":19},"Melanoma",{"name":27,"count":19},"Hepatocellular Carcinoma",{"name":29,"count":30},"Nasopharyngeal Carcinoma",2,{"name":32,"count":30},"Advanced Solid Tumors",[34,39,44,49,54,59,64,67,72,77],{"nctId":35,"briefTitle":36,"date":37,"intervention":38},"NCT05621070","Efficacy and Safety of JS002 as Monotherapy in Patients With Primary Hypercholesterolaemia and Mixed Dyslipidemia","2024-09-23","JS002",{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT06170489","A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL)","2025-05-31","JS004 in combination with Toripalimab",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT04158440","Phase III Study of Toripalimab Versus Placebo Plus Chemotherapy in Resectable NSCLC","2025-06-30","4cycles(Toripalimab IV 240mg + platinum-based doublet chemotherapy)+13 cycles(Toripalimab IV 240mg); Biological: Toripalimab",{"nctId":50,"briefTitle":51,"date":52,"intervention":53},"NCT06139211","A Phase Ib\u002FII Study Of JS015 Combination Therapy in Advanced Solid Tumors","2025-11-01","JS015",{"nctId":55,"briefTitle":56,"date":57,"intervention":58},"NCT06969027","JS207Combined With Chemotherapy in First-line Treatment of Advanced NSCLC","2025-11-30","JS207",{"nctId":60,"briefTitle":61,"date":62,"intervention":63},"NCT04523493","Phase III Study of Toripalimab（JS001） Combined With Lenvatinib for Advanced HCC","2025-12-31","Toripalimab combined with Lenvatinib",{"nctId":65,"briefTitle":66,"date":62,"intervention":58},"NCT06022250","The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of JS207 in Patients With Advanced Malignant Tumor",{"nctId":68,"briefTitle":69,"date":70,"intervention":71},"NCT06571422","Phase I Study of WJ47156 Monotherarpy and in Combination With Other Therapy in Advanced Solid Tumors","2026-05-15","WJ47156",{"nctId":73,"briefTitle":74,"date":75,"intervention":76},"NCT06924606","Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Chemotherapy and Immunotherapy","2026-06-26","JS207 injection +docetaxel",{"nctId":78,"briefTitle":79,"date":80,"intervention":81},"NCT06505837","JS001sc or JS001 Plus Chemotherapy is Indicated for Relapsed or Metastatic First-Line Non-Squamous Non Small Cell Lung Cancer（NSCLC）","2026-06-30","JS001sc (360mg Subcutaneous injection) and pemetrexed\u002Fplatinum-containing chemotherapy",[83,84,85,86,87,88],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[90,335,378,400,470,503,525,547,573,596,614,635,661,679,701,719,737,755,773,791,809,827,845,944,984,1014,1044,1070,1103,1138,1170,1192,1214,1255,1283,1301,1319,1337,1355,1383,1401,1419,1437,1455,1473,1499,1525,1543,1561,1579,1597,1615,1633,1651,1669,1687,1711,1729,1747,1826,1860,1878,1904,1922,1948,1975,1993,2021,2039,2057,2083,2108,2126,2144,2233,2270,2299,2317,2335,2358,2383,2401,2419,2437,2455,2473,2491,2509,2534,2559,2585,2603,2632,2650,2675,2699,2717,2743,2761,2785,2810,2828,2853,2871,2895,2913,2935,2961,2984,3008,3034,3052,3075,3102],{"intervention":91,"totalTrials":92,"cells":93},"Toripalimab",19,{"EARLY_PHASE1":94,"PHASE1":96,"PHASE2":156,"PHASE3":246,"PHASE4":319,"NA":321},{"trials":95,"activeCount":12},[],{"trials":97,"activeCount":12},[98,110,122,134,147],{"nctId":99,"briefTitle":100,"status":101,"phases":102,"primaryCompletion":103,"completion":104,"start":105,"enrollment":106,"conditions":107,"interventions":108},"NCT05502393","A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced or Metastatic Solid Tumors","UNKNOWN",[84],"2024-07-31","2024-12-31","2022-07-26",118,[32],[109,91],"JS107",{"nctId":111,"briefTitle":112,"status":113,"phases":114,"primaryCompletion":115,"completion":115,"start":116,"enrollment":117,"conditions":118,"interventions":120},"NCT05427396","A Phase I Clinical Study of Recombinant Humanized Anti-BTLA Monoclonal Antibody (JS004) Injection Combined With Toripalimab Injection in Patients With Advanced Solid Tumors","TERMINATED",[84],"2024-01-15","2022-07-28",31,[119],"Liver Cancer, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Cervical Cancer, MSI-H Colorectal Cancer",[121,91],"JS004",{"nctId":123,"briefTitle":124,"status":125,"phases":126,"primaryCompletion":127,"completion":128,"start":129,"enrollment":130,"conditions":131,"interventions":133},"NCT03316144","Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Toripalimab for Patients With Recurrent Malignant Lymphoma","COMPLETED",[84],"2018-09-15","2019-12-30","2017-07-12",13,[132],"Malignant Lymphoma",[91],{"nctId":135,"briefTitle":136,"status":137,"phases":138,"primaryCompletion":139,"completion":140,"start":141,"enrollment":12,"conditions":142,"interventions":145},"NCT05253105","A Clinical Study of TAB006 in Patients With Previously Treated, Advanced Malignancies","WITHDRAWN",[84],"2026-09","2027-01","2022-03-15",[143,144],"Previously Treated, Advanced","Malignancies",[146,91],"TAB006",{"nctId":148,"briefTitle":149,"status":125,"phases":150,"primaryCompletion":127,"completion":151,"start":152,"enrollment":153,"conditions":154,"interventions":155},"NCT03301688","The Pharmacokinetics and Safety of Single-dose and Parallel Comparisons in Patients With NSCLC Treated With JS001",[84],"2019-12-15","2017-09-18",38,[21],[91],{"trials":157,"activeCount":19,"soonestReadout":52},[158,176,190,200,212,227,238],{"nctId":50,"briefTitle":51,"status":159,"phases":160,"primaryCompletion":52,"completion":161,"start":162,"enrollment":163,"conditions":164,"interventions":166},"RECRUITING",[84,85],"2026-01-28","2024-01-03",186,[165],"Advanced Solid Tumor",[53,91,167,168,169,170,171,172,173,174,175],"Paclitaxel","Irinotecan","Capecitabine","Oxaliplatin","Bevacizumab","Fluorouracil","Leucovorin","Gemcitabine","Albumin-Bound Paclitaxel",{"nctId":177,"briefTitle":178,"status":159,"phases":179,"primaryCompletion":180,"completion":181,"start":182,"enrollment":183,"conditions":184,"interventions":186},"NCT07480733","Phase II Study of JS212\u002FJS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid Tumors",[85],"2027-11-30","2028-11-11","2026-04-23",410,[185],"Advanced Malignant Solid Tumors",[187,188,189,91],"JS212 for","JS213 for","JS207 for",{"nctId":191,"briefTitle":192,"status":113,"phases":193,"primaryCompletion":194,"completion":194,"start":195,"enrollment":196,"conditions":197,"interventions":198},"NCT03867370","Toripalimab in Combination With Lenvatinib as Neoadjuvant Therapy in Resectable Hepatocellular Carcinoma",[84,85],"2023-08-08","2019-04-26",40,[27],[91,199,199],"Toripalimab (JS001 ) Lenvatinib",{"nctId":201,"briefTitle":202,"status":101,"phases":203,"primaryCompletion":204,"completion":205,"start":206,"enrollment":207,"conditions":208,"interventions":210},"NCT04856631","A Study of Toripalimab Injection (JS001) + Cetuximab in Treatment of Advanced Head and Neck Squamous Cell Cancer",[84,85],"2022-11-30","2023-11-30","2021-04-06",88,[209],"Head and Neck Squamous Cell Cancer",[91,211],"Cetuximab Solution for",{"nctId":213,"briefTitle":214,"status":125,"phases":215,"primaryCompletion":216,"completion":216,"start":217,"enrollment":218,"conditions":219,"interventions":220},"NCT05664971","JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer",[84,85],"2025-10-23","2023-02-09",119,[23],[221,91,222,223,224,225,167,226],"Recombinant humanized anti-BTLA monoclonal antibody (JS004)","Docetaxel","Pemetrexed","Cisplatin","Carboplatin","Etoposide",{"nctId":228,"briefTitle":229,"status":101,"phases":230,"primaryCompletion":231,"completion":232,"start":233,"enrollment":234,"conditions":235,"interventions":237},"NCT04603040","A Study to Evaluate the Efficacy and Safety of Toripalimab Injection in the Treatment of Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy and Are Positive Specific Markers",[85],"2022-12-31","2023-03-31","2020-09-28",100,[236],"Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy",[91],{"nctId":239,"briefTitle":240,"status":159,"phases":241,"primaryCompletion":180,"completion":181,"start":242,"enrollment":243,"conditions":244,"interventions":245},"NCT07309276","A Phase II Clinical Study Evaluating the Combination Therapy of JS212 in Patients With Advanced Lung Cancer",[85],"2026-01-23",864,[23],[187,189,91,188],{"trials":247,"activeCount":30,"soonestReadout":264},[248,260,274,287,298,308],{"nctId":249,"briefTitle":250,"status":101,"phases":251,"primaryCompletion":252,"completion":253,"start":254,"enrollment":255,"conditions":256,"interventions":258},"NCT03924050","Toripalimab Plus Pemetrexed+Platinus in Advanced Non-small-cell Lungcancer Patients Previsouly Treated EGFR-TKI",[86],"2023-07-17","2024-08-08","2019-05-06",440,[257],"Non-small Cell Lung Cancer",[259],"TORIPALIMAB",{"nctId":261,"briefTitle":262,"status":159,"phases":263,"primaryCompletion":264,"completion":264,"start":265,"enrollment":266,"conditions":267,"interventions":269},"NCT05342194","Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study",[86],"2027-05-31","2023-06-19",480,[268],"Intrahepatic Cholangiocarcinoma",[91,270,271,272,273,224],"Lenvatinib mesylate","Oral placebo","Oxaliplatin for","Gemcitabine hydrochloride",{"nctId":275,"briefTitle":276,"status":159,"phases":277,"primaryCompletion":278,"completion":279,"start":280,"enrollment":281,"conditions":282,"interventions":284},"NCT06095583","Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)",[86],"2027-07-31","2029-07-31","2023-11-15",756,[283],"Limited-stage Small Cell Lung Cancer (LS-SCLC)",[285,286],"Tifcemalimab","toripalimab",{"nctId":288,"briefTitle":289,"status":125,"phases":290,"primaryCompletion":291,"completion":292,"start":293,"enrollment":294,"conditions":295,"interventions":297},"NCT03829969","Toripalimab or Placebo With Paclitaxel and Cisplatin in Esophageal Squamous Cell Carcinoma",[86],"2021-03-22","2023-09-30","2019-01-31",514,[296],"Advanced or Metastatic Esophageal Squamous Cell Cancer Without Previous Systemic Chemotherapy",[91],{"nctId":299,"briefTitle":300,"status":101,"phases":301,"primaryCompletion":302,"completion":303,"start":304,"enrollment":305,"conditions":306,"interventions":307},"NCT03859128","Toripalimab or Placebo as Adjuvant Therapy in Hepatocellular Carcinoma After Radical Resection",[85,86],"2023-04-18","2023-08-01","2019-03-05",402,[27],[259],{"nctId":309,"briefTitle":310,"status":101,"phases":311,"primaryCompletion":205,"completion":57,"start":312,"enrollment":313,"conditions":314,"interventions":316},"NCT04568304","A Study Evaluating Toripalimab Injection Combined With Standard Chemotherapy as a First-line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma",[86],"2020-11-30",364,[315],"Locally Advanced or Metastatic Urothelial Carcinoma",[91,317,318],"Gemcitabine Hydrochloride for","Cisplatin for Injection \u002F Carboplatin",{"trials":320,"activeCount":12},[],{"trials":322,"activeCount":12},[323],{"nctId":324,"briefTitle":325,"status":101,"phases":326,"primaryCompletion":327,"completion":328,"start":329,"enrollment":330,"conditions":331,"interventions":334},"NCT04234620","Intensive Medicines Monitoring Study of Toripalimab Monoclonal Injection (Tuoyi) .",[],"2023-02-01","2023-07-05","2020-02-15",800,[25,332,333],"Lung Cance","Breast Cancer",[91],{"intervention":167,"totalTrials":16,"cells":336},{"EARLY_PHASE1":337,"PHASE1":339,"PHASE2":341,"PHASE3":359,"PHASE4":374,"NA":376},{"trials":338,"activeCount":12},[],{"trials":340,"activeCount":12},[],{"trials":342,"activeCount":30,"soonestReadout":52},[343,347,351],{"nctId":50,"briefTitle":51,"status":159,"phases":344,"primaryCompletion":52,"completion":161,"start":162,"enrollment":163,"conditions":345,"interventions":346},[84,85],[165],[53,91,167,168,169,170,171,172,173,174,175],{"nctId":213,"briefTitle":214,"status":125,"phases":348,"primaryCompletion":216,"completion":216,"start":217,"enrollment":218,"conditions":349,"interventions":350},[84,85],[23],[221,91,222,223,224,225,167,226],{"nctId":55,"briefTitle":56,"status":159,"phases":352,"primaryCompletion":57,"completion":353,"start":354,"enrollment":355,"conditions":356,"interventions":357},[85],"2027-12-31","2025-06-19",84,[257],[58,223,358,167],"Platinum",{"trials":360,"activeCount":373,"soonestReadout":365},[361],{"nctId":362,"briefTitle":363,"status":159,"phases":364,"primaryCompletion":365,"completion":366,"start":367,"enrollment":368,"conditions":369,"interventions":371},"NCT07284134","JS107 vs Investigator's Choice as Second-line or Later Therapy for Advanced CLDN18.2-Positive Gastricor GEJ Adenocarcinoma.",[86],"2027-10-13","2028-10-17","2025-12-24",560,[370],"Advanced Gastric or Gastroesophageal Junction Adenocarcinoma",[372,168,167,222],"JS107 for",1,{"trials":375,"activeCount":12},[],{"trials":377,"activeCount":12},[],{"intervention":168,"totalTrials":30,"cells":379},{"EARLY_PHASE1":380,"PHASE1":382,"PHASE2":384,"PHASE3":390,"PHASE4":396,"NA":398},{"trials":381,"activeCount":12},[],{"trials":383,"activeCount":12},[],{"trials":385,"activeCount":373,"soonestReadout":52},[386],{"nctId":50,"briefTitle":51,"status":159,"phases":387,"primaryCompletion":52,"completion":161,"start":162,"enrollment":163,"conditions":388,"interventions":389},[84,85],[165],[53,91,167,168,169,170,171,172,173,174,175],{"trials":391,"activeCount":373,"soonestReadout":365},[392],{"nctId":362,"briefTitle":363,"status":159,"phases":393,"primaryCompletion":365,"completion":366,"start":367,"enrollment":368,"conditions":394,"interventions":395},[86],[370],[372,168,167,222],{"trials":397,"activeCount":12},[],{"trials":399,"activeCount":12},[],{"intervention":38,"totalTrials":401,"cells":402},6,{"EARLY_PHASE1":403,"PHASE1":405,"PHASE2":427,"PHASE3":438,"PHASE4":466,"NA":468},{"trials":404,"activeCount":12},[],{"trials":406,"activeCount":12},[407,416],{"nctId":408,"briefTitle":409,"status":125,"phases":410,"primaryCompletion":411,"completion":411,"start":412,"enrollment":355,"conditions":413,"interventions":415},"NCT04197817","A Single Dose Escalation Study of PCSK9 Inhibitor (JS002) in Health Subjects",[84],"2018-08-14","2017-12-11",[414],"Hypercholesterolemia",[38],{"nctId":417,"briefTitle":418,"status":125,"phases":419,"primaryCompletion":420,"completion":421,"start":422,"enrollment":423,"conditions":424,"interventions":426},"NCT05859529","A Pharmacokinetic Study of JS002 in Healthy Subjects",[84],"2023-06-30","2023-09-11","2023-05-30",318,[425],"Health Volunteer",[38],{"trials":428,"activeCount":12},[429],{"nctId":430,"briefTitle":431,"status":125,"phases":432,"primaryCompletion":433,"completion":434,"start":435,"enrollment":117,"conditions":436,"interventions":437},"NCT04515927","To Evaluate the Efficacy and Safety of JS002 in HoFH Patients",[85],"2022-05-06","2022-07-29","2020-08-17",[15],[38],{"trials":439,"activeCount":373,"soonestReadout":37},[440,450,458],{"nctId":441,"briefTitle":442,"status":125,"phases":443,"primaryCompletion":444,"completion":445,"start":446,"enrollment":447,"conditions":448,"interventions":449},"NCT04781114","The Safety and Efficacy of Multiple-dose of JS002 in Subject With Hyperlipidemia",[86],"2022-05-25","2023-01-16","2020-12-23",806,[15],[38],{"nctId":451,"briefTitle":452,"status":125,"phases":453,"primaryCompletion":217,"completion":217,"start":454,"enrollment":455,"conditions":456,"interventions":457},"NCT05532800","The Efficacy and Safety of JS002 PFS and AI in Patients With Primary Hypercholesterolemia and Mixed Hyperlipidemia",[86],"2022-02-28",255,[15],[38],{"nctId":35,"briefTitle":36,"status":159,"phases":459,"primaryCompletion":37,"completion":460,"start":461,"enrollment":462,"conditions":463,"interventions":465},[86],"2024-09-30","2023-02-03",582,[464],"Primary Hypercholesterolaemia and Mixed Dyslipidemia",[38,38],{"trials":467,"activeCount":12},[],{"trials":469,"activeCount":12},[],{"intervention":471,"totalTrials":30,"cells":472},"JS004 in combination with toripalimab",{"EARLY_PHASE1":473,"PHASE1":475,"PHASE2":477,"PHASE3":488,"PHASE4":499,"NA":501},{"trials":474,"activeCount":12},[],{"trials":476,"activeCount":12},[],{"trials":478,"activeCount":12},[479],{"nctId":480,"briefTitle":481,"status":125,"phases":482,"primaryCompletion":483,"completion":483,"start":484,"enrollment":485,"conditions":486,"interventions":487},"NCT05000684","Study of JS004 Combined With Toripalimab for Advanced Lung Cancer",[84,85],"2024-10-31","2021-08-27",67,[23],[471],{"trials":489,"activeCount":373,"soonestReadout":42},[490],{"nctId":40,"briefTitle":41,"status":159,"phases":491,"primaryCompletion":42,"completion":492,"start":493,"enrollment":494,"conditions":495,"interventions":497},[86],"2027-09-30","2023-12-28",185,[496],"Hodgkin Lymphoma",[43,498],"Bendamustine or gemcitabine",{"trials":500,"activeCount":12},[],{"trials":502,"activeCount":12},[],{"intervention":224,"totalTrials":30,"cells":504},{"EARLY_PHASE1":505,"PHASE1":507,"PHASE2":509,"PHASE3":515,"PHASE4":521,"NA":523},{"trials":506,"activeCount":12},[],{"trials":508,"activeCount":12},[],{"trials":510,"activeCount":12},[511],{"nctId":213,"briefTitle":214,"status":125,"phases":512,"primaryCompletion":216,"completion":216,"start":217,"enrollment":218,"conditions":513,"interventions":514},[84,85],[23],[221,91,222,223,224,225,167,226],{"trials":516,"activeCount":373,"soonestReadout":264},[517],{"nctId":261,"briefTitle":262,"status":159,"phases":518,"primaryCompletion":264,"completion":264,"start":265,"enrollment":266,"conditions":519,"interventions":520},[86],[268],[91,270,271,272,273,224],{"trials":522,"activeCount":12},[],{"trials":524,"activeCount":12},[],{"intervention":222,"totalTrials":30,"cells":526},{"EARLY_PHASE1":527,"PHASE1":529,"PHASE2":531,"PHASE3":537,"PHASE4":543,"NA":545},{"trials":528,"activeCount":12},[],{"trials":530,"activeCount":12},[],{"trials":532,"activeCount":12},[533],{"nctId":213,"briefTitle":214,"status":125,"phases":534,"primaryCompletion":216,"completion":216,"start":217,"enrollment":218,"conditions":535,"interventions":536},[84,85],[23],[221,91,222,223,224,225,167,226],{"trials":538,"activeCount":373,"soonestReadout":365},[539],{"nctId":362,"briefTitle":363,"status":159,"phases":540,"primaryCompletion":365,"completion":366,"start":367,"enrollment":368,"conditions":541,"interventions":542},[86],[370],[372,168,167,222],{"trials":544,"activeCount":12},[],{"trials":546,"activeCount":12},[],{"intervention":548,"totalTrials":373,"cells":549},"Toripalimab combined with cisplatin and paclitaxel",{"EARLY_PHASE1":550,"PHASE1":552,"PHASE2":554,"PHASE3":556,"PHASE4":569,"NA":571},{"trials":551,"activeCount":12},[],{"trials":553,"activeCount":12},[],{"trials":555,"activeCount":12},[],{"trials":557,"activeCount":373,"soonestReadout":563},[558],{"nctId":559,"briefTitle":560,"status":561,"phases":562,"primaryCompletion":563,"completion":563,"start":564,"enrollment":565,"conditions":566,"interventions":568},"NCT04848753","Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma","ACTIVE_NOT_RECRUITING",[86],"2027-05-12","2021-05-12",663,[567],"Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma",[548],{"trials":570,"activeCount":12},[],{"trials":572,"activeCount":12},[],{"intervention":81,"totalTrials":373,"cells":574},{"EARLY_PHASE1":575,"PHASE1":577,"PHASE2":579,"PHASE3":581,"PHASE4":592,"NA":594},{"trials":576,"activeCount":12},[],{"trials":578,"activeCount":12},[],{"trials":580,"activeCount":12},[],{"trials":582,"activeCount":373,"soonestReadout":80},[583],{"nctId":78,"briefTitle":79,"status":561,"phases":584,"primaryCompletion":80,"completion":585,"start":586,"enrollment":587,"conditions":588,"interventions":590},[86],"2026-12-30","2024-07-11",395,[589],"Recurrent Metastatic Non-Squamous Non Small Cell Lung Cancer",[81,591],"JS001 (240mg intravenous infusion) and pemetrexed\u002Fplatinum-containing chemotherapy",{"trials":593,"activeCount":12},[],{"trials":595,"activeCount":12},[],{"intervention":591,"totalTrials":373,"cells":597},{"EARLY_PHASE1":598,"PHASE1":600,"PHASE2":602,"PHASE3":604,"PHASE4":610,"NA":612},{"trials":599,"activeCount":12},[],{"trials":601,"activeCount":12},[],{"trials":603,"activeCount":12},[],{"trials":605,"activeCount":373,"soonestReadout":80},[606],{"nctId":78,"briefTitle":79,"status":561,"phases":607,"primaryCompletion":80,"completion":585,"start":586,"enrollment":587,"conditions":608,"interventions":609},[86],[589],[81,591],{"trials":611,"activeCount":12},[],{"trials":613,"activeCount":12},[],{"intervention":63,"totalTrials":373,"cells":615},{"EARLY_PHASE1":616,"PHASE1":618,"PHASE2":620,"PHASE3":622,"PHASE4":631,"NA":633},{"trials":617,"activeCount":12},[],{"trials":619,"activeCount":12},[],{"trials":621,"activeCount":12},[],{"trials":623,"activeCount":373,"soonestReadout":62},[624],{"nctId":60,"briefTitle":61,"status":561,"phases":625,"primaryCompletion":62,"completion":626,"start":627,"enrollment":628,"conditions":629,"interventions":630},[86],"2026-09-01","2020-06-29",530,[18],[63],{"trials":632,"activeCount":12},[],{"trials":634,"activeCount":12},[],{"intervention":636,"totalTrials":373,"cells":637},"JS001\u002FPlacebo",{"EARLY_PHASE1":638,"PHASE1":640,"PHASE2":642,"PHASE3":644,"PHASE4":657,"NA":659},{"trials":639,"activeCount":12},[],{"trials":641,"activeCount":12},[],{"trials":643,"activeCount":12},[],{"trials":645,"activeCount":373,"soonestReadout":80},[646],{"nctId":647,"briefTitle":648,"status":561,"phases":649,"primaryCompletion":80,"completion":650,"start":651,"enrollment":652,"conditions":653,"interventions":655},"NCT05180734","PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer",[86],"2028-07-31","2022-02-10",878,[654],"Gastric or Esophagogastric Junction Adenocarcinoma",[636,656],"JS001\u002Fplacebo combine with Postoperative Adjuvant Chemotherapy",{"trials":658,"activeCount":12},[],{"trials":660,"activeCount":12},[],{"intervention":656,"totalTrials":373,"cells":662},{"EARLY_PHASE1":663,"PHASE1":665,"PHASE2":667,"PHASE3":669,"PHASE4":675,"NA":677},{"trials":664,"activeCount":12},[],{"trials":666,"activeCount":12},[],{"trials":668,"activeCount":12},[],{"trials":670,"activeCount":373,"soonestReadout":80},[671],{"nctId":647,"briefTitle":648,"status":561,"phases":672,"primaryCompletion":80,"completion":650,"start":651,"enrollment":652,"conditions":673,"interventions":674},[86],[654],[636,656],{"trials":676,"activeCount":12},[],{"trials":678,"activeCount":12},[],{"intervention":48,"totalTrials":373,"cells":680},{"EARLY_PHASE1":681,"PHASE1":683,"PHASE2":685,"PHASE3":687,"PHASE4":697,"NA":699},{"trials":682,"activeCount":12},[],{"trials":684,"activeCount":12},[],{"trials":686,"activeCount":12},[],{"trials":688,"activeCount":373,"soonestReadout":47},[689],{"nctId":45,"briefTitle":46,"status":561,"phases":690,"primaryCompletion":47,"completion":62,"start":691,"enrollment":692,"conditions":693,"interventions":695},[86],"2020-04-07",501,[694],"Stage II-III Non-small Cell Lung Cancer",[48,696],"4cycles",{"trials":698,"activeCount":12},[],{"trials":700,"activeCount":12},[],{"intervention":696,"totalTrials":373,"cells":702},{"EARLY_PHASE1":703,"PHASE1":705,"PHASE2":707,"PHASE3":709,"PHASE4":715,"NA":717},{"trials":704,"activeCount":12},[],{"trials":706,"activeCount":12},[],{"trials":708,"activeCount":12},[],{"trials":710,"activeCount":373,"soonestReadout":47},[711],{"nctId":45,"briefTitle":46,"status":561,"phases":712,"primaryCompletion":47,"completion":62,"start":691,"enrollment":692,"conditions":713,"interventions":714},[86],[694],[48,696],{"trials":716,"activeCount":12},[],{"trials":718,"activeCount":12},[],{"intervention":270,"totalTrials":373,"cells":720},{"EARLY_PHASE1":721,"PHASE1":723,"PHASE2":725,"PHASE3":727,"PHASE4":733,"NA":735},{"trials":722,"activeCount":12},[],{"trials":724,"activeCount":12},[],{"trials":726,"activeCount":12},[],{"trials":728,"activeCount":373,"soonestReadout":264},[729],{"nctId":261,"briefTitle":262,"status":159,"phases":730,"primaryCompletion":264,"completion":264,"start":265,"enrollment":266,"conditions":731,"interventions":732},[86],[268],[91,270,271,272,273,224],{"trials":734,"activeCount":12},[],{"trials":736,"activeCount":12},[],{"intervention":271,"totalTrials":373,"cells":738},{"EARLY_PHASE1":739,"PHASE1":741,"PHASE2":743,"PHASE3":745,"PHASE4":751,"NA":753},{"trials":740,"activeCount":12},[],{"trials":742,"activeCount":12},[],{"trials":744,"activeCount":12},[],{"trials":746,"activeCount":373,"soonestReadout":264},[747],{"nctId":261,"briefTitle":262,"status":159,"phases":748,"primaryCompletion":264,"completion":264,"start":265,"enrollment":266,"conditions":749,"interventions":750},[86],[268],[91,270,271,272,273,224],{"trials":752,"activeCount":12},[],{"trials":754,"activeCount":12},[],{"intervention":272,"totalTrials":373,"cells":756},{"EARLY_PHASE1":757,"PHASE1":759,"PHASE2":761,"PHASE3":763,"PHASE4":769,"NA":771},{"trials":758,"activeCount":12},[],{"trials":760,"activeCount":12},[],{"trials":762,"activeCount":12},[],{"trials":764,"activeCount":373,"soonestReadout":264},[765],{"nctId":261,"briefTitle":262,"status":159,"phases":766,"primaryCompletion":264,"completion":264,"start":265,"enrollment":266,"conditions":767,"interventions":768},[86],[268],[91,270,271,272,273,224],{"trials":770,"activeCount":12},[],{"trials":772,"activeCount":12},[],{"intervention":273,"totalTrials":373,"cells":774},{"EARLY_PHASE1":775,"PHASE1":777,"PHASE2":779,"PHASE3":781,"PHASE4":787,"NA":789},{"trials":776,"activeCount":12},[],{"trials":778,"activeCount":12},[],{"trials":780,"activeCount":12},[],{"trials":782,"activeCount":373,"soonestReadout":264},[783],{"nctId":261,"briefTitle":262,"status":159,"phases":784,"primaryCompletion":264,"completion":264,"start":265,"enrollment":266,"conditions":785,"interventions":786},[86],[268],[91,270,271,272,273,224],{"trials":788,"activeCount":12},[],{"trials":790,"activeCount":12},[],{"intervention":285,"totalTrials":373,"cells":792},{"EARLY_PHASE1":793,"PHASE1":795,"PHASE2":797,"PHASE3":799,"PHASE4":805,"NA":807},{"trials":794,"activeCount":12},[],{"trials":796,"activeCount":12},[],{"trials":798,"activeCount":12},[],{"trials":800,"activeCount":373,"soonestReadout":278},[801],{"nctId":275,"briefTitle":276,"status":159,"phases":802,"primaryCompletion":278,"completion":279,"start":280,"enrollment":281,"conditions":803,"interventions":804},[86],[283],[285,286],{"trials":806,"activeCount":12},[],{"trials":808,"activeCount":12},[],{"intervention":498,"totalTrials":373,"cells":810},{"EARLY_PHASE1":811,"PHASE1":813,"PHASE2":815,"PHASE3":817,"PHASE4":823,"NA":825},{"trials":812,"activeCount":12},[],{"trials":814,"activeCount":12},[],{"trials":816,"activeCount":12},[],{"trials":818,"activeCount":373,"soonestReadout":42},[819],{"nctId":40,"briefTitle":41,"status":159,"phases":820,"primaryCompletion":42,"completion":492,"start":493,"enrollment":494,"conditions":821,"interventions":822},[86],[496],[43,498],{"trials":824,"activeCount":12},[],{"trials":826,"activeCount":12},[],{"intervention":372,"totalTrials":373,"cells":828},{"EARLY_PHASE1":829,"PHASE1":831,"PHASE2":833,"PHASE3":835,"PHASE4":841,"NA":843},{"trials":830,"activeCount":12},[],{"trials":832,"activeCount":12},[],{"trials":834,"activeCount":12},[],{"trials":836,"activeCount":373,"soonestReadout":365},[837],{"nctId":362,"briefTitle":363,"status":159,"phases":838,"primaryCompletion":365,"completion":366,"start":367,"enrollment":368,"conditions":839,"interventions":840},[86],[370],[372,168,167,222],{"trials":842,"activeCount":12},[],{"trials":844,"activeCount":12},[],{"intervention":58,"totalTrials":846,"cells":847},9,{"EARLY_PHASE1":848,"PHASE1":850,"PHASE2":867,"PHASE3":938,"PHASE4":940,"NA":942},{"trials":849,"activeCount":12},[],{"trials":851,"activeCount":30,"soonestReadout":62},[852,859],{"nctId":65,"briefTitle":66,"status":561,"phases":853,"primaryCompletion":62,"completion":80,"start":854,"enrollment":855,"conditions":856,"interventions":858},[84],"2023-09-26",98,[857],"Advanced Malignant Tumor",[58],{"nctId":68,"briefTitle":69,"status":159,"phases":860,"primaryCompletion":70,"completion":861,"start":862,"enrollment":863,"conditions":864,"interventions":865},[84],"2027-04-30","2024-10-23",93,[185],[71,866,58],"JS001+Bevacizumab",{"trials":868,"activeCount":937,"soonestReadout":57},[869,877,888,898,909,922,926],{"nctId":73,"briefTitle":74,"status":159,"phases":870,"primaryCompletion":75,"completion":75,"start":871,"enrollment":872,"conditions":873,"interventions":875},[85],"2025-07-15",66,[874],"Advanced NSCLC",[76,876,58],"JS207 injection +JS004",{"nctId":878,"briefTitle":879,"status":159,"phases":880,"primaryCompletion":881,"completion":882,"start":883,"enrollment":884,"conditions":885,"interventions":887},"NCT06885385","A Phase 2 Study Evaluating the Safety and Efficacy of JS207 With or Without JS015 in Combination With Chemotherapy in Patients With Colorectal Cancer",[85],"2026-11-27","2027-02-13","2025-04-23",60,[886],"Advanced Colorectal Cancer",[58,53,169,170],{"nctId":889,"briefTitle":890,"status":159,"phases":891,"primaryCompletion":353,"completion":892,"start":893,"enrollment":894,"conditions":895,"interventions":896},"NCT06954467","JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma",[85],"2028-06-30","2025-05-29",72,[27],[58,897],"JS007",{"nctId":899,"briefTitle":900,"status":901,"phases":902,"primaryCompletion":903,"completion":353,"start":904,"enrollment":905,"conditions":906,"interventions":907},"NCT06944470","JS207 Combined With Chemotherapy in Subjects With Stage II-III NSCLC","NOT_YET_RECRUITING",[85],"2026-09-30","2025-04-20",76,[21],[908,58],"Paclitaxel + Carboplatin\u002Fcisplatin for squamous cell carcinoma and pemetrexed + carboplatin\u002Fcisplatin for non-squamous cell carcinoma",{"nctId":910,"briefTitle":911,"status":159,"phases":912,"primaryCompletion":913,"completion":914,"start":915,"enrollment":916,"conditions":917,"interventions":919},"NCT06868836","Phase II Clinical Study of JS207 (PD-1\u002FVEGF Bispecific Antibody) Combination Therapies in Patients With Driver Gene-Positive, Advanced Non-Small Cell Lung Cancer After Failure of TKI Therapy",[85],"2026-09-04","2028-04-04","2025-03-30",78,[918],"Non-squamous Non-small Cell Lung Cancer",[58,223,920,921],"Carboplatin or cisplatin","JS212",{"nctId":55,"briefTitle":56,"status":159,"phases":923,"primaryCompletion":57,"completion":353,"start":354,"enrollment":355,"conditions":924,"interventions":925},[85],[257],[58,223,358,167],{"nctId":927,"briefTitle":928,"status":159,"phases":929,"primaryCompletion":930,"completion":931,"start":932,"enrollment":933,"conditions":934,"interventions":936},"NCT07503756","JS212 Combination Therapies in Metastatic Colorectal Cancer",[85],"2027-12-30","2028-03-30","2026-04-25",80,[935],"Metastatic Colorectal Cancer",[921,169,171,170,58],7,{"trials":939,"activeCount":12},[],{"trials":941,"activeCount":12},[],{"trials":943,"activeCount":12},[],{"intervention":169,"totalTrials":16,"cells":945},{"EARLY_PHASE1":946,"PHASE1":948,"PHASE2":964,"PHASE3":978,"PHASE4":980,"NA":982},{"trials":947,"activeCount":12},[],{"trials":949,"activeCount":373,"soonestReadout":954},[950],{"nctId":951,"briefTitle":952,"status":159,"phases":953,"primaryCompletion":954,"completion":954,"start":955,"enrollment":956,"conditions":957,"interventions":959},"NCT06839105","A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies",[84],"2028-04-30","2025-02-21",214,[958],"Non-Small Cell Lung Cancer, Colorectal Cancer, Renal Cell Carcinoma, Melanoma and Other Solid Tumor",[960,961,223,170,169,171,962,963],"Taxol","Cisplatin or Carboplatin","Renvastinib","AWT020",{"trials":965,"activeCount":19,"soonestReadout":52},[966,970,974],{"nctId":50,"briefTitle":51,"status":159,"phases":967,"primaryCompletion":52,"completion":161,"start":162,"enrollment":163,"conditions":968,"interventions":969},[84,85],[165],[53,91,167,168,169,170,171,172,173,174,175],{"nctId":878,"briefTitle":879,"status":159,"phases":971,"primaryCompletion":881,"completion":882,"start":883,"enrollment":884,"conditions":972,"interventions":973},[85],[886],[58,53,169,170],{"nctId":927,"briefTitle":928,"status":159,"phases":975,"primaryCompletion":930,"completion":931,"start":932,"enrollment":933,"conditions":976,"interventions":977},[85],[935],[921,169,171,170,58],{"trials":979,"activeCount":12},[],{"trials":981,"activeCount":12},[],{"trials":983,"activeCount":12},[],{"intervention":170,"totalTrials":16,"cells":985},{"EARLY_PHASE1":986,"PHASE1":988,"PHASE2":994,"PHASE3":1008,"PHASE4":1010,"NA":1012},{"trials":987,"activeCount":12},[],{"trials":989,"activeCount":373,"soonestReadout":954},[990],{"nctId":951,"briefTitle":952,"status":159,"phases":991,"primaryCompletion":954,"completion":954,"start":955,"enrollment":956,"conditions":992,"interventions":993},[84],[958],[960,961,223,170,169,171,962,963],{"trials":995,"activeCount":19,"soonestReadout":52},[996,1000,1004],{"nctId":50,"briefTitle":51,"status":159,"phases":997,"primaryCompletion":52,"completion":161,"start":162,"enrollment":163,"conditions":998,"interventions":999},[84,85],[165],[53,91,167,168,169,170,171,172,173,174,175],{"nctId":878,"briefTitle":879,"status":159,"phases":1001,"primaryCompletion":881,"completion":882,"start":883,"enrollment":884,"conditions":1002,"interventions":1003},[85],[886],[58,53,169,170],{"nctId":927,"briefTitle":928,"status":159,"phases":1005,"primaryCompletion":930,"completion":931,"start":932,"enrollment":933,"conditions":1006,"interventions":1007},[85],[935],[921,169,171,170,58],{"trials":1009,"activeCount":12},[],{"trials":1011,"activeCount":12},[],{"trials":1013,"activeCount":12},[],{"intervention":223,"totalTrials":16,"cells":1015},{"EARLY_PHASE1":1016,"PHASE1":1018,"PHASE2":1024,"PHASE3":1038,"PHASE4":1040,"NA":1042},{"trials":1017,"activeCount":12},[],{"trials":1019,"activeCount":373,"soonestReadout":954},[1020],{"nctId":951,"briefTitle":952,"status":159,"phases":1021,"primaryCompletion":954,"completion":954,"start":955,"enrollment":956,"conditions":1022,"interventions":1023},[84],[958],[960,961,223,170,169,171,962,963],{"trials":1025,"activeCount":30,"soonestReadout":57},[1026,1030,1034],{"nctId":213,"briefTitle":214,"status":125,"phases":1027,"primaryCompletion":216,"completion":216,"start":217,"enrollment":218,"conditions":1028,"interventions":1029},[84,85],[23],[221,91,222,223,224,225,167,226],{"nctId":910,"briefTitle":911,"status":159,"phases":1031,"primaryCompletion":913,"completion":914,"start":915,"enrollment":916,"conditions":1032,"interventions":1033},[85],[918],[58,223,920,921],{"nctId":55,"briefTitle":56,"status":159,"phases":1035,"primaryCompletion":57,"completion":353,"start":354,"enrollment":355,"conditions":1036,"interventions":1037},[85],[257],[58,223,358,167],{"trials":1039,"activeCount":12},[],{"trials":1041,"activeCount":12},[],{"trials":1043,"activeCount":12},[],{"intervention":171,"totalTrials":19,"cells":1045},{"EARLY_PHASE1":1046,"PHASE1":1048,"PHASE2":1054,"PHASE3":1064,"PHASE4":1066,"NA":1068},{"trials":1047,"activeCount":12},[],{"trials":1049,"activeCount":373,"soonestReadout":954},[1050],{"nctId":951,"briefTitle":952,"status":159,"phases":1051,"primaryCompletion":954,"completion":954,"start":955,"enrollment":956,"conditions":1052,"interventions":1053},[84],[958],[960,961,223,170,169,171,962,963],{"trials":1055,"activeCount":30,"soonestReadout":52},[1056,1060],{"nctId":50,"briefTitle":51,"status":159,"phases":1057,"primaryCompletion":52,"completion":161,"start":162,"enrollment":163,"conditions":1058,"interventions":1059},[84,85],[165],[53,91,167,168,169,170,171,172,173,174,175],{"nctId":927,"briefTitle":928,"status":159,"phases":1061,"primaryCompletion":930,"completion":931,"start":932,"enrollment":933,"conditions":1062,"interventions":1063},[85],[935],[921,169,171,170,58],{"trials":1065,"activeCount":12},[],{"trials":1067,"activeCount":12},[],{"trials":1069,"activeCount":12},[],{"intervention":187,"totalTrials":19,"cells":1071},{"EARLY_PHASE1":1072,"PHASE1":1074,"PHASE2":1076,"PHASE3":1097,"PHASE4":1099,"NA":1101},{"trials":1073,"activeCount":12},[],{"trials":1075,"activeCount":12},[],{"trials":1077,"activeCount":19,"soonestReadout":1082},[1078,1089,1093],{"nctId":1079,"briefTitle":1080,"status":159,"phases":1081,"primaryCompletion":1082,"completion":1083,"start":1084,"enrollment":1085,"conditions":1086,"interventions":1088},"NCT06888830","A Phase I\u002FII Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Initial Efficacy of JS212 in Subjects With Advanced Malignant Solid Tumour",[84,85],"2026-07-01","2027-04-01","2025-04-11",374,[1087],"Advanced Malignant Solid Tumours",[187],{"nctId":177,"briefTitle":178,"status":159,"phases":1090,"primaryCompletion":180,"completion":181,"start":182,"enrollment":183,"conditions":1091,"interventions":1092},[85],[185],[187,188,189,91],{"nctId":239,"briefTitle":240,"status":159,"phases":1094,"primaryCompletion":180,"completion":181,"start":242,"enrollment":243,"conditions":1095,"interventions":1096},[85],[23],[187,189,91,188],{"trials":1098,"activeCount":12},[],{"trials":1100,"activeCount":12},[],{"trials":1102,"activeCount":12},[],{"intervention":921,"totalTrials":19,"cells":1104},{"EARLY_PHASE1":1105,"PHASE1":1107,"PHASE2":1109,"PHASE3":1132,"PHASE4":1134,"NA":1136},{"trials":1106,"activeCount":12},[],{"trials":1108,"activeCount":12},[],{"trials":1110,"activeCount":19,"soonestReadout":913},[1111,1124,1128],{"nctId":1112,"briefTitle":1113,"status":159,"phases":1114,"primaryCompletion":1115,"completion":1116,"start":1117,"enrollment":1118,"conditions":1119,"interventions":1121},"NCT07484724","A Study Evaluating the Safety and Efficacy of JS212 Combination Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma",[85],"2027-06-30","2028-04-01","2026-04-13",280,[1120],"Advanced Esophageal Squamous Cell Carcinoma",[921,1122,1123],"JS001","5-FU",{"nctId":910,"briefTitle":911,"status":159,"phases":1125,"primaryCompletion":913,"completion":914,"start":915,"enrollment":916,"conditions":1126,"interventions":1127},[85],[918],[58,223,920,921],{"nctId":927,"briefTitle":928,"status":159,"phases":1129,"primaryCompletion":930,"completion":931,"start":932,"enrollment":933,"conditions":1130,"interventions":1131},[85],[935],[921,169,171,170,58],{"trials":1133,"activeCount":12},[],{"trials":1135,"activeCount":12},[],{"trials":1137,"activeCount":12},[],{"intervention":53,"totalTrials":19,"cells":1139},{"EARLY_PHASE1":1140,"PHASE1":1142,"PHASE2":1154,"PHASE3":1164,"PHASE4":1166,"NA":1168},{"trials":1141,"activeCount":12},[],{"trials":1143,"activeCount":12},[1144],{"nctId":1145,"briefTitle":1146,"status":101,"phases":1147,"primaryCompletion":1148,"completion":1149,"start":327,"enrollment":1150,"conditions":1151,"interventions":1153},"NCT05770310","A Phase I Study Of JS015 in Patients With Advanced Solid Tumors",[84],"2024-06-01","2025-07-01",114,[1152],"Advanced Solid Cancer",[53],{"trials":1155,"activeCount":30,"soonestReadout":52},[1156,1160],{"nctId":50,"briefTitle":51,"status":159,"phases":1157,"primaryCompletion":52,"completion":161,"start":162,"enrollment":163,"conditions":1158,"interventions":1159},[84,85],[165],[53,91,167,168,169,170,171,172,173,174,175],{"nctId":878,"briefTitle":879,"status":159,"phases":1161,"primaryCompletion":881,"completion":882,"start":883,"enrollment":884,"conditions":1162,"interventions":1163},[85],[886],[58,53,169,170],{"trials":1165,"activeCount":12},[],{"trials":1167,"activeCount":12},[],{"trials":1169,"activeCount":12},[],{"intervention":188,"totalTrials":30,"cells":1171},{"EARLY_PHASE1":1172,"PHASE1":1174,"PHASE2":1176,"PHASE3":1186,"PHASE4":1188,"NA":1190},{"trials":1173,"activeCount":12},[],{"trials":1175,"activeCount":12},[],{"trials":1177,"activeCount":30,"soonestReadout":180},[1178,1182],{"nctId":177,"briefTitle":178,"status":159,"phases":1179,"primaryCompletion":180,"completion":181,"start":182,"enrollment":183,"conditions":1180,"interventions":1181},[85],[185],[187,188,189,91],{"nctId":239,"briefTitle":240,"status":159,"phases":1183,"primaryCompletion":180,"completion":181,"start":242,"enrollment":243,"conditions":1184,"interventions":1185},[85],[23],[187,189,91,188],{"trials":1187,"activeCount":12},[],{"trials":1189,"activeCount":12},[],{"trials":1191,"activeCount":12},[],{"intervention":189,"totalTrials":30,"cells":1193},{"EARLY_PHASE1":1194,"PHASE1":1196,"PHASE2":1198,"PHASE3":1208,"PHASE4":1210,"NA":1212},{"trials":1195,"activeCount":12},[],{"trials":1197,"activeCount":12},[],{"trials":1199,"activeCount":30,"soonestReadout":180},[1200,1204],{"nctId":177,"briefTitle":178,"status":159,"phases":1201,"primaryCompletion":180,"completion":181,"start":182,"enrollment":183,"conditions":1202,"interventions":1203},[85],[185],[187,188,189,91],{"nctId":239,"briefTitle":240,"status":159,"phases":1205,"primaryCompletion":180,"completion":181,"start":242,"enrollment":243,"conditions":1206,"interventions":1207},[85],[23],[187,189,91,188],{"trials":1209,"activeCount":12},[],{"trials":1211,"activeCount":12},[],{"trials":1213,"activeCount":12},[],{"intervention":1122,"totalTrials":19,"cells":1215},{"EARLY_PHASE1":1216,"PHASE1":1218,"PHASE2":1232,"PHASE3":1238,"PHASE4":1251,"NA":1253},{"trials":1217,"activeCount":12},[],{"trials":1219,"activeCount":12},[1220],{"nctId":1221,"briefTitle":1222,"status":101,"phases":1223,"primaryCompletion":1224,"completion":1225,"start":1226,"enrollment":1227,"conditions":1228,"interventions":1231},"NCT02836834","Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of an Anti-PD-1 mAb for Patients With Advanced Solid Tumors",[84],"2020-09","2020-12","2016-08",33,[1229,1230],"Lymphoma","Lung Cancer",[1122],{"trials":1233,"activeCount":373,"soonestReadout":1115},[1234],{"nctId":1112,"briefTitle":1113,"status":159,"phases":1235,"primaryCompletion":1115,"completion":1116,"start":1117,"enrollment":1118,"conditions":1236,"interventions":1237},[85],[1120],[921,1122,1123],{"trials":1239,"activeCount":12},[1240],{"nctId":1241,"briefTitle":1242,"status":125,"phases":1243,"primaryCompletion":104,"completion":1244,"start":1245,"enrollment":1246,"conditions":1247,"interventions":1249},"NCT04085276","Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment",[86],"2025-02-28","2018-12-21",531,[1248],"Triple-Negative Breast Cancer",[1122,1250,1250],"Nab-Paclitaxel",{"trials":1252,"activeCount":12},[],{"trials":1254,"activeCount":12},[],{"intervention":897,"totalTrials":30,"cells":1256},{"EARLY_PHASE1":1257,"PHASE1":1259,"PHASE2":1271,"PHASE3":1277,"PHASE4":1279,"NA":1281},{"trials":1258,"activeCount":12},[],{"trials":1260,"activeCount":12},[1261],{"nctId":1262,"briefTitle":1263,"status":101,"phases":1264,"primaryCompletion":1265,"completion":1265,"start":1266,"enrollment":1267,"conditions":1268,"interventions":1270},"NCT05049265","Clinical Study of JS007 in Patients With Advanced Solid Tumors",[84],"2022-09-20","2021-11-17",42,[1269],"Patients With Advanced Solid Tumors",[897],{"trials":1272,"activeCount":373,"soonestReadout":353},[1273],{"nctId":889,"briefTitle":890,"status":159,"phases":1274,"primaryCompletion":353,"completion":892,"start":893,"enrollment":894,"conditions":1275,"interventions":1276},[85],[27],[58,897],{"trials":1278,"activeCount":12},[],{"trials":1280,"activeCount":12},[],{"trials":1282,"activeCount":12},[],{"intervention":172,"totalTrials":373,"cells":1284},{"EARLY_PHASE1":1285,"PHASE1":1287,"PHASE2":1289,"PHASE3":1295,"PHASE4":1297,"NA":1299},{"trials":1286,"activeCount":12},[],{"trials":1288,"activeCount":12},[],{"trials":1290,"activeCount":373,"soonestReadout":52},[1291],{"nctId":50,"briefTitle":51,"status":159,"phases":1292,"primaryCompletion":52,"completion":161,"start":162,"enrollment":163,"conditions":1293,"interventions":1294},[84,85],[165],[53,91,167,168,169,170,171,172,173,174,175],{"trials":1296,"activeCount":12},[],{"trials":1298,"activeCount":12},[],{"trials":1300,"activeCount":12},[],{"intervention":173,"totalTrials":373,"cells":1302},{"EARLY_PHASE1":1303,"PHASE1":1305,"PHASE2":1307,"PHASE3":1313,"PHASE4":1315,"NA":1317},{"trials":1304,"activeCount":12},[],{"trials":1306,"activeCount":12},[],{"trials":1308,"activeCount":373,"soonestReadout":52},[1309],{"nctId":50,"briefTitle":51,"status":159,"phases":1310,"primaryCompletion":52,"completion":161,"start":162,"enrollment":163,"conditions":1311,"interventions":1312},[84,85],[165],[53,91,167,168,169,170,171,172,173,174,175],{"trials":1314,"activeCount":12},[],{"trials":1316,"activeCount":12},[],{"trials":1318,"activeCount":12},[],{"intervention":174,"totalTrials":373,"cells":1320},{"EARLY_PHASE1":1321,"PHASE1":1323,"PHASE2":1325,"PHASE3":1331,"PHASE4":1333,"NA":1335},{"trials":1322,"activeCount":12},[],{"trials":1324,"activeCount":12},[],{"trials":1326,"activeCount":373,"soonestReadout":52},[1327],{"nctId":50,"briefTitle":51,"status":159,"phases":1328,"primaryCompletion":52,"completion":161,"start":162,"enrollment":163,"conditions":1329,"interventions":1330},[84,85],[165],[53,91,167,168,169,170,171,172,173,174,175],{"trials":1332,"activeCount":12},[],{"trials":1334,"activeCount":12},[],{"trials":1336,"activeCount":12},[],{"intervention":175,"totalTrials":373,"cells":1338},{"EARLY_PHASE1":1339,"PHASE1":1341,"PHASE2":1343,"PHASE3":1349,"PHASE4":1351,"NA":1353},{"trials":1340,"activeCount":12},[],{"trials":1342,"activeCount":12},[],{"trials":1344,"activeCount":373,"soonestReadout":52},[1345],{"nctId":50,"briefTitle":51,"status":159,"phases":1346,"primaryCompletion":52,"completion":161,"start":162,"enrollment":163,"conditions":1347,"interventions":1348},[84,85],[165],[53,91,167,168,169,170,171,172,173,174,175],{"trials":1350,"activeCount":12},[],{"trials":1352,"activeCount":12},[],{"trials":1354,"activeCount":12},[],{"intervention":1356,"totalTrials":373,"cells":1357},"JS203 in combination with gemcitabine and oxaliplatin",{"EARLY_PHASE1":1358,"PHASE1":1360,"PHASE2":1362,"PHASE3":1377,"PHASE4":1379,"NA":1381},{"trials":1359,"activeCount":12},[],{"trials":1361,"activeCount":12},[],{"trials":1363,"activeCount":373,"soonestReadout":1368},[1364],{"nctId":1365,"briefTitle":1366,"status":159,"phases":1367,"primaryCompletion":1368,"completion":1368,"start":1369,"enrollment":1370,"conditions":1371,"interventions":1373},"NCT07081022","JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma",[85],"2027-04-06","2025-08-17",180,[1372],"B-cell Non-Hodgkin's Lymphoma",[1356,1374,1375,1376],"JS203 in combination with ifosfamide, carboplatin and etoposide","JS203 in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone","JS203 combined with lenalidomide",{"trials":1378,"activeCount":12},[],{"trials":1380,"activeCount":12},[],{"trials":1382,"activeCount":12},[],{"intervention":1374,"totalTrials":373,"cells":1384},{"EARLY_PHASE1":1385,"PHASE1":1387,"PHASE2":1389,"PHASE3":1395,"PHASE4":1397,"NA":1399},{"trials":1386,"activeCount":12},[],{"trials":1388,"activeCount":12},[],{"trials":1390,"activeCount":373,"soonestReadout":1368},[1391],{"nctId":1365,"briefTitle":1366,"status":159,"phases":1392,"primaryCompletion":1368,"completion":1368,"start":1369,"enrollment":1370,"conditions":1393,"interventions":1394},[85],[1372],[1356,1374,1375,1376],{"trials":1396,"activeCount":12},[],{"trials":1398,"activeCount":12},[],{"trials":1400,"activeCount":12},[],{"intervention":1375,"totalTrials":373,"cells":1402},{"EARLY_PHASE1":1403,"PHASE1":1405,"PHASE2":1407,"PHASE3":1413,"PHASE4":1415,"NA":1417},{"trials":1404,"activeCount":12},[],{"trials":1406,"activeCount":12},[],{"trials":1408,"activeCount":373,"soonestReadout":1368},[1409],{"nctId":1365,"briefTitle":1366,"status":159,"phases":1410,"primaryCompletion":1368,"completion":1368,"start":1369,"enrollment":1370,"conditions":1411,"interventions":1412},[85],[1372],[1356,1374,1375,1376],{"trials":1414,"activeCount":12},[],{"trials":1416,"activeCount":12},[],{"trials":1418,"activeCount":12},[],{"intervention":1376,"totalTrials":373,"cells":1420},{"EARLY_PHASE1":1421,"PHASE1":1423,"PHASE2":1425,"PHASE3":1431,"PHASE4":1433,"NA":1435},{"trials":1422,"activeCount":12},[],{"trials":1424,"activeCount":12},[],{"trials":1426,"activeCount":373,"soonestReadout":1368},[1427],{"nctId":1365,"briefTitle":1366,"status":159,"phases":1428,"primaryCompletion":1368,"completion":1368,"start":1369,"enrollment":1370,"conditions":1429,"interventions":1430},[85],[1372],[1356,1374,1375,1376],{"trials":1432,"activeCount":12},[],{"trials":1434,"activeCount":12},[],{"trials":1436,"activeCount":12},[],{"intervention":76,"totalTrials":373,"cells":1438},{"EARLY_PHASE1":1439,"PHASE1":1441,"PHASE2":1443,"PHASE3":1449,"PHASE4":1451,"NA":1453},{"trials":1440,"activeCount":12},[],{"trials":1442,"activeCount":12},[],{"trials":1444,"activeCount":373,"soonestReadout":75},[1445],{"nctId":73,"briefTitle":74,"status":159,"phases":1446,"primaryCompletion":75,"completion":75,"start":871,"enrollment":872,"conditions":1447,"interventions":1448},[85],[874],[76,876,58],{"trials":1450,"activeCount":12},[],{"trials":1452,"activeCount":12},[],{"trials":1454,"activeCount":12},[],{"intervention":876,"totalTrials":373,"cells":1456},{"EARLY_PHASE1":1457,"PHASE1":1459,"PHASE2":1461,"PHASE3":1467,"PHASE4":1469,"NA":1471},{"trials":1458,"activeCount":12},[],{"trials":1460,"activeCount":12},[],{"trials":1462,"activeCount":373,"soonestReadout":75},[1463],{"nctId":73,"briefTitle":74,"status":159,"phases":1464,"primaryCompletion":75,"completion":75,"start":871,"enrollment":872,"conditions":1465,"interventions":1466},[85],[874],[76,876,58],{"trials":1468,"activeCount":12},[],{"trials":1470,"activeCount":12},[],{"trials":1472,"activeCount":12},[],{"intervention":1474,"totalTrials":373,"cells":1475},"JS212 for Injection＋JS111",{"EARLY_PHASE1":1476,"PHASE1":1478,"PHASE2":1480,"PHASE3":1493,"PHASE4":1495,"NA":1497},{"trials":1477,"activeCount":12},[],{"trials":1479,"activeCount":12},[],{"trials":1481,"activeCount":373,"soonestReadout":1486},[1482],{"nctId":1483,"briefTitle":1484,"status":901,"phases":1485,"primaryCompletion":1486,"completion":1487,"start":1488,"enrollment":1489,"conditions":1490,"interventions":1492},"NCT07518160","JS212 Plus JS111 in EGFR-Mutant Advanced NSCLC: A Phase II Study",[85],"2028-04-23","2029-04-23","2026-03-23",35,[1491],"Locally Advanced, Metastatic, or Recurrent Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations",[1474],{"trials":1494,"activeCount":12},[],{"trials":1496,"activeCount":12},[],{"trials":1498,"activeCount":12},[],{"intervention":1500,"totalTrials":373,"cells":1501},"JS207 in combination with 9MW2821",{"EARLY_PHASE1":1502,"PHASE1":1504,"PHASE2":1506,"PHASE3":1519,"PHASE4":1521,"NA":1523},{"trials":1503,"activeCount":12},[],{"trials":1505,"activeCount":12},[],{"trials":1507,"activeCount":373,"soonestReadout":1512},[1508],{"nctId":1509,"briefTitle":1510,"status":159,"phases":1511,"primaryCompletion":1512,"completion":1513,"start":1514,"enrollment":933,"conditions":1515,"interventions":1517},"NCT07045311","JS207 Combination Therapy in Triple-negative Breast Cancer",[85],"2028-03-22","2029-03-22","2025-09-17",[1516],"Triple-negative Breast Cancer",[1500,1518],"JS207 in combination with Albumin paclitaxel",{"trials":1520,"activeCount":12},[],{"trials":1522,"activeCount":12},[],{"trials":1524,"activeCount":12},[],{"intervention":1518,"totalTrials":373,"cells":1526},{"EARLY_PHASE1":1527,"PHASE1":1529,"PHASE2":1531,"PHASE3":1537,"PHASE4":1539,"NA":1541},{"trials":1528,"activeCount":12},[],{"trials":1530,"activeCount":12},[],{"trials":1532,"activeCount":373,"soonestReadout":1512},[1533],{"nctId":1509,"briefTitle":1510,"status":159,"phases":1534,"primaryCompletion":1512,"completion":1513,"start":1514,"enrollment":933,"conditions":1535,"interventions":1536},[85],[1516],[1500,1518],{"trials":1538,"activeCount":12},[],{"trials":1540,"activeCount":12},[],{"trials":1542,"activeCount":12},[],{"intervention":908,"totalTrials":373,"cells":1544},{"EARLY_PHASE1":1545,"PHASE1":1547,"PHASE2":1549,"PHASE3":1555,"PHASE4":1557,"NA":1559},{"trials":1546,"activeCount":12},[],{"trials":1548,"activeCount":12},[],{"trials":1550,"activeCount":373,"soonestReadout":903},[1551],{"nctId":899,"briefTitle":900,"status":901,"phases":1552,"primaryCompletion":903,"completion":353,"start":904,"enrollment":905,"conditions":1553,"interventions":1554},[85],[21],[908,58],{"trials":1556,"activeCount":12},[],{"trials":1558,"activeCount":12},[],{"trials":1560,"activeCount":12},[],{"intervention":1123,"totalTrials":373,"cells":1562},{"EARLY_PHASE1":1563,"PHASE1":1565,"PHASE2":1567,"PHASE3":1573,"PHASE4":1575,"NA":1577},{"trials":1564,"activeCount":12},[],{"trials":1566,"activeCount":12},[],{"trials":1568,"activeCount":373,"soonestReadout":1115},[1569],{"nctId":1112,"briefTitle":1113,"status":159,"phases":1570,"primaryCompletion":1115,"completion":1116,"start":1117,"enrollment":1118,"conditions":1571,"interventions":1572},[85],[1120],[921,1122,1123],{"trials":1574,"activeCount":12},[],{"trials":1576,"activeCount":12},[],{"trials":1578,"activeCount":12},[],{"intervention":920,"totalTrials":373,"cells":1580},{"EARLY_PHASE1":1581,"PHASE1":1583,"PHASE2":1585,"PHASE3":1591,"PHASE4":1593,"NA":1595},{"trials":1582,"activeCount":12},[],{"trials":1584,"activeCount":12},[],{"trials":1586,"activeCount":373,"soonestReadout":913},[1587],{"nctId":910,"briefTitle":911,"status":159,"phases":1588,"primaryCompletion":913,"completion":914,"start":915,"enrollment":916,"conditions":1589,"interventions":1590},[85],[918],[58,223,920,921],{"trials":1592,"activeCount":12},[],{"trials":1594,"activeCount":12},[],{"trials":1596,"activeCount":12},[],{"intervention":358,"totalTrials":373,"cells":1598},{"EARLY_PHASE1":1599,"PHASE1":1601,"PHASE2":1603,"PHASE3":1609,"PHASE4":1611,"NA":1613},{"trials":1600,"activeCount":12},[],{"trials":1602,"activeCount":12},[],{"trials":1604,"activeCount":373,"soonestReadout":57},[1605],{"nctId":55,"briefTitle":56,"status":159,"phases":1606,"primaryCompletion":57,"completion":353,"start":354,"enrollment":355,"conditions":1607,"interventions":1608},[85],[257],[58,223,358,167],{"trials":1610,"activeCount":12},[],{"trials":1612,"activeCount":12},[],{"trials":1614,"activeCount":12},[],{"intervention":960,"totalTrials":373,"cells":1616},{"EARLY_PHASE1":1617,"PHASE1":1619,"PHASE2":1625,"PHASE3":1627,"PHASE4":1629,"NA":1631},{"trials":1618,"activeCount":12},[],{"trials":1620,"activeCount":373,"soonestReadout":954},[1621],{"nctId":951,"briefTitle":952,"status":159,"phases":1622,"primaryCompletion":954,"completion":954,"start":955,"enrollment":956,"conditions":1623,"interventions":1624},[84],[958],[960,961,223,170,169,171,962,963],{"trials":1626,"activeCount":12},[],{"trials":1628,"activeCount":12},[],{"trials":1630,"activeCount":12},[],{"trials":1632,"activeCount":12},[],{"intervention":961,"totalTrials":373,"cells":1634},{"EARLY_PHASE1":1635,"PHASE1":1637,"PHASE2":1643,"PHASE3":1645,"PHASE4":1647,"NA":1649},{"trials":1636,"activeCount":12},[],{"trials":1638,"activeCount":373,"soonestReadout":954},[1639],{"nctId":951,"briefTitle":952,"status":159,"phases":1640,"primaryCompletion":954,"completion":954,"start":955,"enrollment":956,"conditions":1641,"interventions":1642},[84],[958],[960,961,223,170,169,171,962,963],{"trials":1644,"activeCount":12},[],{"trials":1646,"activeCount":12},[],{"trials":1648,"activeCount":12},[],{"trials":1650,"activeCount":12},[],{"intervention":962,"totalTrials":373,"cells":1652},{"EARLY_PHASE1":1653,"PHASE1":1655,"PHASE2":1661,"PHASE3":1663,"PHASE4":1665,"NA":1667},{"trials":1654,"activeCount":12},[],{"trials":1656,"activeCount":373,"soonestReadout":954},[1657],{"nctId":951,"briefTitle":952,"status":159,"phases":1658,"primaryCompletion":954,"completion":954,"start":955,"enrollment":956,"conditions":1659,"interventions":1660},[84],[958],[960,961,223,170,169,171,962,963],{"trials":1662,"activeCount":12},[],{"trials":1664,"activeCount":12},[],{"trials":1666,"activeCount":12},[],{"trials":1668,"activeCount":12},[],{"intervention":963,"totalTrials":373,"cells":1670},{"EARLY_PHASE1":1671,"PHASE1":1673,"PHASE2":1679,"PHASE3":1681,"PHASE4":1683,"NA":1685},{"trials":1672,"activeCount":12},[],{"trials":1674,"activeCount":373,"soonestReadout":954},[1675],{"nctId":951,"briefTitle":952,"status":159,"phases":1676,"primaryCompletion":954,"completion":954,"start":955,"enrollment":956,"conditions":1677,"interventions":1678},[84],[958],[960,961,223,170,169,171,962,963],{"trials":1680,"activeCount":12},[],{"trials":1682,"activeCount":12},[],{"trials":1684,"activeCount":12},[],{"trials":1686,"activeCount":12},[],{"intervention":1688,"totalTrials":373,"cells":1689},"JS203 for",{"EARLY_PHASE1":1690,"PHASE1":1692,"PHASE2":1703,"PHASE3":1705,"PHASE4":1707,"NA":1709},{"trials":1691,"activeCount":12},[],{"trials":1693,"activeCount":373,"soonestReadout":585},[1694],{"nctId":1695,"briefTitle":1696,"status":561,"phases":1697,"primaryCompletion":585,"completion":585,"start":1698,"enrollment":1699,"conditions":1700,"interventions":1702},"NCT05618327","Phase I Clinical Study of JS203 in Patients With Relapsed\u002FRefractory B-cell Non-Hodgkin's Lymphoma",[84],"2023-02-13",104,[1701],"Relapsed\u002FRefractory B-cell Non-Hodgkin's Lymphoma",[1688],{"trials":1704,"activeCount":12},[],{"trials":1706,"activeCount":12},[],{"trials":1708,"activeCount":12},[],{"trials":1710,"activeCount":12},[],{"intervention":71,"totalTrials":373,"cells":1712},{"EARLY_PHASE1":1713,"PHASE1":1715,"PHASE2":1721,"PHASE3":1723,"PHASE4":1725,"NA":1727},{"trials":1714,"activeCount":12},[],{"trials":1716,"activeCount":373,"soonestReadout":70},[1717],{"nctId":68,"briefTitle":69,"status":159,"phases":1718,"primaryCompletion":70,"completion":861,"start":862,"enrollment":863,"conditions":1719,"interventions":1720},[84],[185],[71,866,58],{"trials":1722,"activeCount":12},[],{"trials":1724,"activeCount":12},[],{"trials":1726,"activeCount":12},[],{"trials":1728,"activeCount":12},[],{"intervention":866,"totalTrials":373,"cells":1730},{"EARLY_PHASE1":1731,"PHASE1":1733,"PHASE2":1739,"PHASE3":1741,"PHASE4":1743,"NA":1745},{"trials":1732,"activeCount":12},[],{"trials":1734,"activeCount":373,"soonestReadout":70},[1735],{"nctId":68,"briefTitle":69,"status":159,"phases":1736,"primaryCompletion":70,"completion":861,"start":862,"enrollment":863,"conditions":1737,"interventions":1738},[84],[185],[71,866,58],{"trials":1740,"activeCount":12},[],{"trials":1742,"activeCount":12},[],{"trials":1744,"activeCount":12},[],{"trials":1746,"activeCount":12},[],{"intervention":1748,"totalTrials":401,"cells":1749},"JS005",{"EARLY_PHASE1":1750,"PHASE1":1752,"PHASE2":1774,"PHASE3":1809,"PHASE4":1822,"NA":1824},{"trials":1751,"activeCount":12},[],{"trials":1753,"activeCount":12},[1754,1764],{"nctId":1755,"briefTitle":1756,"status":101,"phases":1757,"primaryCompletion":1758,"completion":1759,"start":1760,"enrollment":196,"conditions":1761,"interventions":1763},"NCT04220073","Phase I Study of Comparing Single Dose JS005 (Recombinant Humanized Monoclonal Antibody Against IL-17A) With Placebo in Tolerability, Safety, Immunogenicity and Pharmacokinetic in Healthy Volunteers",[84],"2020-09-21","2021-01-17","2020-01-05",[1762],"Tolerability, Safety, Immunogenicity and Pharmacokinetic of JS005",[1748],{"nctId":1765,"briefTitle":1766,"status":125,"phases":1767,"primaryCompletion":1768,"completion":1769,"start":1770,"enrollment":1771,"conditions":1772,"interventions":1773},"NCT06732973","A Bioequivalence Study of JS005 Pre-filled Syringe and JS005 Auto-injector",[84],"2025-06-06","2025-10-21","2024-12-20",272,[425],[1748],{"trials":1775,"activeCount":12},[1776,1787,1797],{"nctId":1777,"briefTitle":1778,"status":101,"phases":1779,"primaryCompletion":1780,"completion":1781,"start":1782,"enrollment":1783,"conditions":1784,"interventions":1786},"NCT05242588","Evaluate the Preliminary Efficacy, Safety, and PK of Subcutaneous JS005 in Chinese Adult Patients With Active Nr-axSpA",[85],"2023-04-01","2023-06-10","2022-01-26",120,[1785],"Non-radiographic Axial Spondyloarthritis",[1748],{"nctId":1788,"briefTitle":1789,"status":101,"phases":1790,"primaryCompletion":1791,"completion":1792,"start":1793,"enrollment":1783,"conditions":1794,"interventions":1796},"NCT05212051","Evaluate the Preliminary Efficacy, Safety, and PK of Subcutaneous JS005 in Chinese Adult Patients With Active AS",[85],"2022-11-02","2023-01-11","2021-12-10",[1795],"Active Ankylosing Spondylitis",[1748],{"nctId":1798,"briefTitle":1799,"status":125,"phases":1800,"primaryCompletion":1801,"completion":1802,"start":1803,"enrollment":1804,"conditions":1805,"interventions":1807},"NCT05344248","Safety, Tolerance, Efficacy and Pharmacokinetics of JS005 Multiple Dosing",[84,85],"2022-10-28","2022-11-01","2021-01-20",183,[1806],"Moderate to Severe Psoriasis",[1748,1808],"JS005 placebo",{"trials":1810,"activeCount":12},[1811],{"nctId":1812,"briefTitle":1813,"status":125,"phases":1814,"primaryCompletion":1815,"completion":1816,"start":1817,"enrollment":1818,"conditions":1819,"interventions":1821},"NCT05975268","A Clinical Study to Evaluate the Efficacy and Safety of Subcutaneous JS005 Injection in the Treatment of Adults With Moderate to Severe Chronic Plaque Psoriasis",[86],"2025-08-20","2025-09-03","2023-08-28",747,[1820],"Moderate to Severe Chronic Plaque Psoriasis",[1748],{"trials":1823,"activeCount":12},[],{"trials":1825,"activeCount":12},[],{"intervention":1827,"totalTrials":30,"cells":1828},"Toripalimab combined with Bevacizumab",{"EARLY_PHASE1":1829,"PHASE1":1831,"PHASE2":1833,"PHASE3":1844,"PHASE4":1856,"NA":1858},{"trials":1830,"activeCount":12},[],{"trials":1832,"activeCount":12},[],{"trials":1834,"activeCount":12},[1835],{"nctId":1836,"briefTitle":1837,"status":101,"phases":1838,"primaryCompletion":1839,"completion":231,"start":1840,"enrollment":1841,"conditions":1842,"interventions":1843},"NCT04605796","A Single-arm, Open-label, Multi-center Phase II Clinical Study to Evaluate the Safety and Efficacy of Toripalimab Injection (JS001) Combined With Bevacizumab as the First-line Therapy for Advanced Hepatocellular Carcinoma (HCC)",[85],"2020-12-22","2020-04-10",54,[18],[1827],{"trials":1845,"activeCount":12},[1846],{"nctId":1847,"briefTitle":1848,"status":101,"phases":1849,"primaryCompletion":1850,"completion":104,"start":1851,"enrollment":1852,"conditions":1853,"interventions":1854},"NCT04723004","Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC",[86],"2023-10-31","2020-10-15",326,[18],[1827,1855],"Sorafenib",{"trials":1857,"activeCount":12},[],{"trials":1859,"activeCount":12},[],{"intervention":1250,"totalTrials":373,"cells":1861},{"EARLY_PHASE1":1862,"PHASE1":1864,"PHASE2":1866,"PHASE3":1868,"PHASE4":1874,"NA":1876},{"trials":1863,"activeCount":12},[],{"trials":1865,"activeCount":12},[],{"trials":1867,"activeCount":12},[],{"trials":1869,"activeCount":12},[1870],{"nctId":1241,"briefTitle":1242,"status":125,"phases":1871,"primaryCompletion":104,"completion":1244,"start":1245,"enrollment":1246,"conditions":1872,"interventions":1873},[86],[1248],[1122,1250,1250],{"trials":1875,"activeCount":12},[],{"trials":1877,"activeCount":12},[],{"intervention":1879,"totalTrials":373,"cells":1880},"Biological : Toripalimab Drug: Axitinib",{"EARLY_PHASE1":1881,"PHASE1":1883,"PHASE2":1885,"PHASE3":1887,"PHASE4":1900,"NA":1902},{"trials":1882,"activeCount":12},[],{"trials":1884,"activeCount":12},[],{"trials":1886,"activeCount":12},[],{"trials":1888,"activeCount":12},[1889],{"nctId":1890,"briefTitle":1891,"status":125,"phases":1892,"primaryCompletion":1893,"completion":1893,"start":1894,"enrollment":1895,"conditions":1896,"interventions":1898},"NCT04394975","Study to Evaluate the Efficacy and Safety of Toripalimab in Combination With Axitinib Versus Sunitinib Monotherapy in Advanced Renal Cell Cancer",[86],"2024-04-02","2020-08-20",421,[1897],"Primary Disease: Unresectable or Metastatic Renal Cell Carcinoma Focus of the Study:PFS Assessed by IRC Per RECIST 1.1",[1879,1899],"sunitinib",{"trials":1901,"activeCount":12},[],{"trials":1903,"activeCount":12},[],{"intervention":1899,"totalTrials":373,"cells":1905},{"EARLY_PHASE1":1906,"PHASE1":1908,"PHASE2":1910,"PHASE3":1912,"PHASE4":1918,"NA":1920},{"trials":1907,"activeCount":12},[],{"trials":1909,"activeCount":12},[],{"trials":1911,"activeCount":12},[],{"trials":1913,"activeCount":12},[1914],{"nctId":1890,"briefTitle":1891,"status":125,"phases":1915,"primaryCompletion":1893,"completion":1893,"start":1894,"enrollment":1895,"conditions":1916,"interventions":1917},[86],[1897],[1879,1899],{"trials":1919,"activeCount":12},[],{"trials":1921,"activeCount":12},[],{"intervention":1923,"totalTrials":373,"cells":1924},"Ongericimab",{"EARLY_PHASE1":1925,"PHASE1":1927,"PHASE2":1929,"PHASE3":1931,"PHASE4":1944,"NA":1946},{"trials":1926,"activeCount":12},[],{"trials":1928,"activeCount":12},[],{"trials":1930,"activeCount":12},[],{"trials":1932,"activeCount":12},[1933],{"nctId":1934,"briefTitle":1935,"status":125,"phases":1936,"primaryCompletion":1937,"completion":1938,"start":1939,"enrollment":1940,"conditions":1941,"interventions":1943},"NCT05325203","A Study to Evaluate the Efficacy and Safety of JS002 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH).",[86],"2023-05-08","2023-06-29","2021-12-31",135,[1942],"Heterozygous Familial Hypercholesterolemia",[1923],{"trials":1945,"activeCount":12},[],{"trials":1947,"activeCount":12},[],{"intervention":1949,"totalTrials":373,"cells":1950},"TORIPALIMAB INJECTION(JS001 ) combine with chemotherapy",{"EARLY_PHASE1":1951,"PHASE1":1953,"PHASE2":1955,"PHASE3":1957,"PHASE4":1971,"NA":1973},{"trials":1952,"activeCount":12},[],{"trials":1954,"activeCount":12},[],{"trials":1956,"activeCount":12},[],{"trials":1958,"activeCount":12},[1959],{"nctId":1960,"briefTitle":1961,"status":125,"phases":1962,"primaryCompletion":1963,"completion":1964,"start":1965,"enrollment":1966,"conditions":1967,"interventions":1969},"NCT03581786","The Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal Cancer",[86],"2020-05-30","2022-11-18","2018-10-18",289,[1968],"Recurrent or Metastatic NPC",[1949,1970],"Placebos",{"trials":1972,"activeCount":12},[],{"trials":1974,"activeCount":12},[],{"intervention":1970,"totalTrials":373,"cells":1976},{"EARLY_PHASE1":1977,"PHASE1":1979,"PHASE2":1981,"PHASE3":1983,"PHASE4":1989,"NA":1991},{"trials":1978,"activeCount":12},[],{"trials":1980,"activeCount":12},[],{"trials":1982,"activeCount":12},[],{"trials":1984,"activeCount":12},[1985],{"nctId":1960,"briefTitle":1961,"status":125,"phases":1986,"primaryCompletion":1963,"completion":1964,"start":1965,"enrollment":1966,"conditions":1987,"interventions":1988},[86],[1968],[1949,1970],{"trials":1990,"activeCount":12},[],{"trials":1992,"activeCount":12},[],{"intervention":1994,"totalTrials":373,"cells":1995},"JS001 240mg Q2W",{"EARLY_PHASE1":1996,"PHASE1":1998,"PHASE2":2000,"PHASE3":2002,"PHASE4":2017,"NA":2019},{"trials":1997,"activeCount":12},[],{"trials":1999,"activeCount":12},[],{"trials":2001,"activeCount":12},[],{"trials":2003,"activeCount":12},[2004],{"nctId":2005,"briefTitle":2006,"status":125,"phases":2007,"primaryCompletion":2008,"completion":2009,"start":2010,"enrollment":2011,"conditions":2012,"interventions":2015},"NCT03430297","A Randomized, Controlled, Multi-center, Phase III Clinical Study to Investigate Recombinant Humanized PD-1 Monoclonal Antibody Injection (JS001) Versus Dacarbazine as the 1st-line Therapy for Unresectable or Metastatic Melanoma",[86],"2023-07-12","2023-11-27","2018-02-02",256,[2013,2014],"Metastatic Melanoma","Unresectable Melanoma",[1994,2016],"Dacarbazine 1000mg\u002Fm2 Q3W",{"trials":2018,"activeCount":12},[],{"trials":2020,"activeCount":12},[],{"intervention":2016,"totalTrials":373,"cells":2022},{"EARLY_PHASE1":2023,"PHASE1":2025,"PHASE2":2027,"PHASE3":2029,"PHASE4":2035,"NA":2037},{"trials":2024,"activeCount":12},[],{"trials":2026,"activeCount":12},[],{"trials":2028,"activeCount":12},[],{"trials":2030,"activeCount":12},[2031],{"nctId":2005,"briefTitle":2006,"status":125,"phases":2032,"primaryCompletion":2008,"completion":2009,"start":2010,"enrollment":2011,"conditions":2033,"interventions":2034},[86],[2013,2014],[1994,2016],{"trials":2036,"activeCount":12},[],{"trials":2038,"activeCount":12},[],{"intervention":1855,"totalTrials":373,"cells":2040},{"EARLY_PHASE1":2041,"PHASE1":2043,"PHASE2":2045,"PHASE3":2047,"PHASE4":2053,"NA":2055},{"trials":2042,"activeCount":12},[],{"trials":2044,"activeCount":12},[],{"trials":2046,"activeCount":12},[],{"trials":2048,"activeCount":12},[2049],{"nctId":1847,"briefTitle":1848,"status":101,"phases":2050,"primaryCompletion":1850,"completion":104,"start":1851,"enrollment":1852,"conditions":2051,"interventions":2052},[86],[18],[1827,1855],{"trials":2054,"activeCount":12},[],{"trials":2056,"activeCount":12},[],{"intervention":2058,"totalTrials":373,"cells":2059},"TORIPALIMAB INJECTION (JS001 ) combine with chemotherapy",{"EARLY_PHASE1":2060,"PHASE1":2062,"PHASE2":2064,"PHASE3":2066,"PHASE4":2079,"NA":2081},{"trials":2061,"activeCount":12},[],{"trials":2063,"activeCount":12},[],{"trials":2065,"activeCount":12},[],{"trials":2067,"activeCount":12},[2068],{"nctId":2069,"briefTitle":2070,"status":125,"phases":2071,"primaryCompletion":2072,"completion":2073,"start":2074,"enrollment":2075,"conditions":2076,"interventions":2078},"NCT03856411","A Study to Evaluate the Efficacy and Safety of Toripalimab or Placebo Combined With Chemotherapy in Treatment-naive Advanced NSCLC",[86],"2022-08-31","2023-01-09","2019-03-18",465,[2077],"Treatment-naive Advanced Non-small Cell Lung Cancer",[2058],{"trials":2080,"activeCount":12},[],{"trials":2082,"activeCount":12},[],{"intervention":2084,"totalTrials":373,"cells":2085},"TORIPALIMAB INJECTION(JS001 ) Carboplatin Cisplatin Etoposide Placebo",{"EARLY_PHASE1":2086,"PHASE1":2088,"PHASE2":2090,"PHASE3":2092,"PHASE4":2104,"NA":2106},{"trials":2087,"activeCount":12},[],{"trials":2089,"activeCount":12},[],{"trials":2091,"activeCount":12},[],{"trials":2093,"activeCount":12},[2094],{"nctId":2095,"briefTitle":2096,"status":125,"phases":2097,"primaryCompletion":2098,"completion":2098,"start":2099,"enrollment":2100,"conditions":2101,"interventions":2103},"NCT04012606","Toripalimab in Combination With Platinum Plus Etoposidein Patients With Extensive-Stage Small Cell Lung Cancer",[86],"2023-04-20","2019-07-23",442,[2102],"Small Cell Lung Cancer",[2084],{"trials":2105,"activeCount":12},[],{"trials":2107,"activeCount":12},[],{"intervention":317,"totalTrials":373,"cells":2109},{"EARLY_PHASE1":2110,"PHASE1":2112,"PHASE2":2114,"PHASE3":2116,"PHASE4":2122,"NA":2124},{"trials":2111,"activeCount":12},[],{"trials":2113,"activeCount":12},[],{"trials":2115,"activeCount":12},[],{"trials":2117,"activeCount":12},[2118],{"nctId":309,"briefTitle":310,"status":101,"phases":2119,"primaryCompletion":205,"completion":57,"start":312,"enrollment":313,"conditions":2120,"interventions":2121},[86],[315],[91,317,318],{"trials":2123,"activeCount":12},[],{"trials":2125,"activeCount":12},[],{"intervention":318,"totalTrials":373,"cells":2127},{"EARLY_PHASE1":2128,"PHASE1":2130,"PHASE2":2132,"PHASE3":2134,"PHASE4":2140,"NA":2142},{"trials":2129,"activeCount":12},[],{"trials":2131,"activeCount":12},[],{"trials":2133,"activeCount":12},[],{"trials":2135,"activeCount":12},[2136],{"nctId":309,"briefTitle":310,"status":101,"phases":2137,"primaryCompletion":205,"completion":57,"start":312,"enrollment":313,"conditions":2138,"interventions":2139},[86],[315],[91,317,318],{"trials":2141,"activeCount":12},[],{"trials":2143,"activeCount":12},[],{"intervention":2145,"totalTrials":937,"cells":2146},"humanized anti-PD-1 monoclonal antibody toripalimab",{"EARLY_PHASE1":2147,"PHASE1":2149,"PHASE2":2192,"PHASE3":2227,"PHASE4":2229,"NA":2231},{"trials":2148,"activeCount":12},[],{"trials":2150,"activeCount":12},[2151,2162,2173,2182],{"nctId":2152,"briefTitle":2153,"status":125,"phases":2154,"primaryCompletion":2155,"completion":2156,"start":2157,"enrollment":2158,"conditions":2159,"interventions":2161},"NCT02857166","Study of JS001 in Participants With Advanced Solid Tumors",[84],"2017-09","2018-12","2016-03",24,[2160],"Solid Tumors",[2145],{"nctId":2163,"briefTitle":2164,"status":101,"phases":2165,"primaryCompletion":2166,"completion":1225,"start":2167,"enrollment":2158,"conditions":2168,"interventions":2171},"NCT03086174","Tolerability and Pharmacokinetics of Toripalimab in Combination With Axitinib in Patients With Kidney Cancer and Melanoma",[84],"2019-12-31","2017-03-31",[2169,2170],"Kidney Cancer Stage Iv","Advanced Melanoma",[2172],"humanized anti-PD-1 monoclonal antibody Toripalimab",{"nctId":2174,"briefTitle":2175,"status":125,"phases":2176,"primaryCompletion":2156,"completion":2177,"start":2178,"enrollment":2179,"conditions":2180,"interventions":2181},"NCT02838823","Safety and Tolerability of Recombinant Humanized Anti-PD-1 Monoclonal Antibody for Patients With Advanced Breast Cancer",[84],"2019-09","2016-07",20,[333],[2145],{"nctId":2183,"briefTitle":2184,"status":125,"phases":2185,"primaryCompletion":2186,"completion":2187,"start":2188,"enrollment":1489,"conditions":2189,"interventions":2191},"NCT02836795","Safety and Tolerability of Recombinant Humanized Anti-PD-1 Monoclonal Antibody Toripalimab for Patients With Advanced Solid Tumors",[84],"2018-09","2018-12-17","2016-04",[25,2190],"Urological Cancer",[2172],{"trials":2193,"activeCount":12},[2194,2205,2217],{"nctId":2195,"briefTitle":2196,"status":101,"phases":2197,"primaryCompletion":2198,"completion":2199,"start":2200,"enrollment":2201,"conditions":2202,"interventions":2204},"NCT03113266","Safety and Efficacy of Toripalimab for Patients With Locally Advanced or Metastatic Bladder Urothelial Carcinoma",[85],"2020-03-15","2022-02","2017-04-06",370,[2203],"Bladder Urothelial Carcinoma",[2145],{"nctId":2206,"briefTitle":2207,"status":101,"phases":2208,"primaryCompletion":2209,"completion":2210,"start":2211,"enrollment":2212,"conditions":2213,"interventions":2215},"NCT03178123","The Study of JS001 Compared to High-Dose Interferon In Patients With Mucosal Melanoma That Has Been Removed by Surgery",[85],"2022-04-30","2025-04-30","2017-05-31",220,[2214],"Mucosal Melanoma",[2172,2216],"high-dose recombinant interferon a-2B",{"nctId":2218,"briefTitle":2219,"status":101,"phases":2220,"primaryCompletion":2221,"completion":2222,"start":2223,"enrollment":2224,"conditions":2225,"interventions":2226},"NCT03013101","Safety and Efficacy of Recombinant Humanized Anti-PD-1 mAb for Patients With Locally Advanced or Metastatic Melanoma",[85],"2018-09-16","2021-12","2016-12-28",128,[2170,2013],[2145],{"trials":2228,"activeCount":12},[],{"trials":2230,"activeCount":12},[],{"trials":2232,"activeCount":12},[],{"intervention":2234,"totalTrials":30,"cells":2235},"JS004 , Recombinant humanized IgG4k monoclonal antibody specific to BTLA for injection Intravenous",{"EARLY_PHASE1":2236,"PHASE1":2238,"PHASE2":2251,"PHASE3":2264,"PHASE4":2266,"NA":2268},{"trials":2237,"activeCount":12},[],{"trials":2239,"activeCount":12},[2240],{"nctId":2241,"briefTitle":2242,"status":125,"phases":2243,"primaryCompletion":2244,"completion":2244,"start":2245,"enrollment":2246,"conditions":2247,"interventions":2249},"NCT04477772","A Phase I Clinical Study of JS004 in Subjects With Recurrent\u002FRefractory Malignant Lymphoma of China",[84],"2024-03-14","2020-07-17",71,[2248],"Recurrent\u002FRefractory Malignant Lymphoma",[2234,2250],"Drug：JS001, Intravenous",{"trials":2252,"activeCount":12},[2253],{"nctId":2254,"briefTitle":2255,"status":125,"phases":2256,"primaryCompletion":2257,"completion":2257,"start":2258,"enrollment":2259,"conditions":2260,"interventions":2262},"NCT04929080","The Safety and Efficacy of Multiple-dose of JS004 in Subject With HNC",[84,85],"2023-03-06","2021-05-11",149,[2261,29],"Head and Neck Squamous Cell Carcinom",[2234,2234,2263],"JS001 and JS004",{"trials":2265,"activeCount":12},[],{"trials":2267,"activeCount":12},[],{"trials":2269,"activeCount":12},[],{"intervention":2271,"totalTrials":373,"cells":2272},"3 mg\u002Fkg anti-PD-1 mAb JS001 Q2W",{"EARLY_PHASE1":2273,"PHASE1":2275,"PHASE2":2277,"PHASE3":2293,"PHASE4":2295,"NA":2297},{"trials":2274,"activeCount":12},[],{"trials":2276,"activeCount":12},[],{"trials":2278,"activeCount":12},[2279],{"nctId":2280,"briefTitle":2281,"status":101,"phases":2282,"primaryCompletion":2283,"completion":2209,"start":2284,"enrollment":2285,"conditions":2286,"interventions":2290},"NCT02915432","The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC",[84,85],"2020-02-19","2016-12",401,[2287,2288,29,2289],"Gastric Adenocarcinoma","Esophageal Squamous Cell Carcinoma","Head and Neck Squamous Cell Carcinoma",[2271,2291,2292],"360 mg anti-PD-1 mAb JS001 Q3W","240mg anti-PD-1 mAb JS001 Q3W",{"trials":2294,"activeCount":12},[],{"trials":2296,"activeCount":12},[],{"trials":2298,"activeCount":12},[],{"intervention":2291,"totalTrials":373,"cells":2300},{"EARLY_PHASE1":2301,"PHASE1":2303,"PHASE2":2305,"PHASE3":2311,"PHASE4":2313,"NA":2315},{"trials":2302,"activeCount":12},[],{"trials":2304,"activeCount":12},[],{"trials":2306,"activeCount":12},[2307],{"nctId":2280,"briefTitle":2281,"status":101,"phases":2308,"primaryCompletion":2283,"completion":2209,"start":2284,"enrollment":2285,"conditions":2309,"interventions":2310},[84,85],[2287,2288,29,2289],[2271,2291,2292],{"trials":2312,"activeCount":12},[],{"trials":2314,"activeCount":12},[],{"trials":2316,"activeCount":12},[],{"intervention":2292,"totalTrials":373,"cells":2318},{"EARLY_PHASE1":2319,"PHASE1":2321,"PHASE2":2323,"PHASE3":2329,"PHASE4":2331,"NA":2333},{"trials":2320,"activeCount":12},[],{"trials":2322,"activeCount":12},[],{"trials":2324,"activeCount":12},[2325],{"nctId":2280,"briefTitle":2281,"status":101,"phases":2326,"primaryCompletion":2283,"completion":2209,"start":2284,"enrollment":2285,"conditions":2327,"interventions":2328},[84,85],[2287,2288,29,2289],[2271,2291,2292],{"trials":2330,"activeCount":12},[],{"trials":2332,"activeCount":12},[],{"trials":2334,"activeCount":12},[],{"intervention":2336,"totalTrials":373,"cells":2337},"Drug intervention",{"EARLY_PHASE1":2338,"PHASE1":2340,"PHASE2":2342,"PHASE3":2352,"PHASE4":2354,"NA":2356},{"trials":2339,"activeCount":12},[],{"trials":2341,"activeCount":12},[],{"trials":2343,"activeCount":12},[2344],{"nctId":2345,"briefTitle":2346,"status":125,"phases":2347,"primaryCompletion":2348,"completion":2348,"start":2349,"enrollment":196,"conditions":2350,"interventions":2351},"NCT03513666","A Study of Toripalimab+ Pemetrexed Plus Carboplatin in Patients With EGFR-mutation Positive and T790M Negative After Progression on EGFR-TKI Treatment",[85],"2022-08-12","2018-04-09",[21],[2336],{"trials":2353,"activeCount":12},[],{"trials":2355,"activeCount":12},[],{"trials":2357,"activeCount":12},[],{"intervention":2359,"totalTrials":373,"cells":2360},"Recombinant Human Anti-SARS-CoV-2 Monoclonal Antibody",{"EARLY_PHASE1":2361,"PHASE1":2363,"PHASE2":2365,"PHASE3":2377,"PHASE4":2379,"NA":2381},{"trials":2362,"activeCount":12},[],{"trials":2364,"activeCount":12},[],{"trials":2366,"activeCount":12},[2367],{"nctId":2368,"briefTitle":2369,"status":125,"phases":2370,"primaryCompletion":2371,"completion":2371,"start":2372,"enrollment":2373,"conditions":2374,"interventions":2376},"NCT04780321","JS016 (Anti-SARS-CoV-2 Monoclonal Antibody)With Mild and Moderate COVID-19 or SARS-CoV-2 Asymptomatic Infection Subects",[84,85],"2021-08-31","2020-10-30",62,[2375],"COVID-19",[2359],{"trials":2378,"activeCount":12},[],{"trials":2380,"activeCount":12},[],{"trials":2382,"activeCount":12},[],{"intervention":2216,"totalTrials":373,"cells":2384},{"EARLY_PHASE1":2385,"PHASE1":2387,"PHASE2":2389,"PHASE3":2395,"PHASE4":2397,"NA":2399},{"trials":2386,"activeCount":12},[],{"trials":2388,"activeCount":12},[],{"trials":2390,"activeCount":12},[2391],{"nctId":2206,"briefTitle":2207,"status":101,"phases":2392,"primaryCompletion":2209,"completion":2210,"start":2211,"enrollment":2212,"conditions":2393,"interventions":2394},[85],[2214],[2172,2216],{"trials":2396,"activeCount":12},[],{"trials":2398,"activeCount":12},[],{"trials":2400,"activeCount":12},[],{"intervention":2263,"totalTrials":373,"cells":2402},{"EARLY_PHASE1":2403,"PHASE1":2405,"PHASE2":2407,"PHASE3":2413,"PHASE4":2415,"NA":2417},{"trials":2404,"activeCount":12},[],{"trials":2406,"activeCount":12},[],{"trials":2408,"activeCount":12},[2409],{"nctId":2254,"briefTitle":2255,"status":125,"phases":2410,"primaryCompletion":2257,"completion":2257,"start":2258,"enrollment":2259,"conditions":2411,"interventions":2412},[84,85],[2261,29],[2234,2234,2263],{"trials":2414,"activeCount":12},[],{"trials":2416,"activeCount":12},[],{"trials":2418,"activeCount":12},[],{"intervention":199,"totalTrials":373,"cells":2420},{"EARLY_PHASE1":2421,"PHASE1":2423,"PHASE2":2425,"PHASE3":2431,"PHASE4":2433,"NA":2435},{"trials":2422,"activeCount":12},[],{"trials":2424,"activeCount":12},[],{"trials":2426,"activeCount":12},[2427],{"nctId":191,"briefTitle":192,"status":113,"phases":2428,"primaryCompletion":194,"completion":194,"start":195,"enrollment":196,"conditions":2429,"interventions":2430},[84,85],[27],[91,199,199],{"trials":2432,"activeCount":12},[],{"trials":2434,"activeCount":12},[],{"trials":2436,"activeCount":12},[],{"intervention":211,"totalTrials":373,"cells":2438},{"EARLY_PHASE1":2439,"PHASE1":2441,"PHASE2":2443,"PHASE3":2449,"PHASE4":2451,"NA":2453},{"trials":2440,"activeCount":12},[],{"trials":2442,"activeCount":12},[],{"trials":2444,"activeCount":12},[2445],{"nctId":201,"briefTitle":202,"status":101,"phases":2446,"primaryCompletion":204,"completion":205,"start":206,"enrollment":207,"conditions":2447,"interventions":2448},[84,85],[209],[91,211],{"trials":2450,"activeCount":12},[],{"trials":2452,"activeCount":12},[],{"trials":2454,"activeCount":12},[],{"intervention":221,"totalTrials":373,"cells":2456},{"EARLY_PHASE1":2457,"PHASE1":2459,"PHASE2":2461,"PHASE3":2467,"PHASE4":2469,"NA":2471},{"trials":2458,"activeCount":12},[],{"trials":2460,"activeCount":12},[],{"trials":2462,"activeCount":12},[2463],{"nctId":213,"briefTitle":214,"status":125,"phases":2464,"primaryCompletion":216,"completion":216,"start":217,"enrollment":218,"conditions":2465,"interventions":2466},[84,85],[23],[221,91,222,223,224,225,167,226],{"trials":2468,"activeCount":12},[],{"trials":2470,"activeCount":12},[],{"trials":2472,"activeCount":12},[],{"intervention":225,"totalTrials":373,"cells":2474},{"EARLY_PHASE1":2475,"PHASE1":2477,"PHASE2":2479,"PHASE3":2485,"PHASE4":2487,"NA":2489},{"trials":2476,"activeCount":12},[],{"trials":2478,"activeCount":12},[],{"trials":2480,"activeCount":12},[2481],{"nctId":213,"briefTitle":214,"status":125,"phases":2482,"primaryCompletion":216,"completion":216,"start":217,"enrollment":218,"conditions":2483,"interventions":2484},[84,85],[23],[221,91,222,223,224,225,167,226],{"trials":2486,"activeCount":12},[],{"trials":2488,"activeCount":12},[],{"trials":2490,"activeCount":12},[],{"intervention":226,"totalTrials":373,"cells":2492},{"EARLY_PHASE1":2493,"PHASE1":2495,"PHASE2":2497,"PHASE3":2503,"PHASE4":2505,"NA":2507},{"trials":2494,"activeCount":12},[],{"trials":2496,"activeCount":12},[],{"trials":2498,"activeCount":12},[2499],{"nctId":213,"briefTitle":214,"status":125,"phases":2500,"primaryCompletion":216,"completion":216,"start":217,"enrollment":218,"conditions":2501,"interventions":2502},[84,85],[23],[221,91,222,223,224,225,167,226],{"trials":2504,"activeCount":12},[],{"trials":2506,"activeCount":12},[],{"trials":2508,"activeCount":12},[],{"intervention":2510,"totalTrials":373,"cells":2511},"Biological：JS002",{"EARLY_PHASE1":2512,"PHASE1":2514,"PHASE2":2516,"PHASE3":2528,"PHASE4":2530,"NA":2532},{"trials":2513,"activeCount":12},[],{"trials":2515,"activeCount":12},[],{"trials":2517,"activeCount":12},[2518],{"nctId":2519,"briefTitle":2520,"status":125,"phases":2521,"primaryCompletion":2522,"completion":2523,"start":2524,"enrollment":2525,"conditions":2526,"interventions":2527},"NCT04469673","A Study to Evaluate the Safety, Tolerability and Efficacy of Multiple Doses of JS002 in Patients With Hyperlipidemia..",[84,85],"2020-05-03","2020-06-28","2019-05-23",90,[15],[2510],{"trials":2529,"activeCount":12},[],{"trials":2531,"activeCount":12},[],{"trials":2533,"activeCount":12},[],{"intervention":2535,"totalTrials":373,"cells":2536},"Glumetinib combined with Toripalimab",{"EARLY_PHASE1":2537,"PHASE1":2539,"PHASE2":2541,"PHASE3":2553,"PHASE4":2555,"NA":2557},{"trials":2538,"activeCount":12},[],{"trials":2540,"activeCount":12},[],{"trials":2542,"activeCount":12},[2543],{"nctId":2544,"briefTitle":2545,"status":101,"phases":2546,"primaryCompletion":2547,"completion":2548,"start":2549,"enrollment":485,"conditions":2550,"interventions":2552},"NCT04797702","Glumetinib Combined With Toripalimab in the Treatment of Relapsed or Metastatic Non-small Cell Lung Cancer.",[84,85],"2023-07-31","2024-02-26","2021-04-15",[2551],"Relapsed or Metastatic Non-small Cell Lung Cancer",[2535],{"trials":2554,"activeCount":12},[],{"trials":2556,"activeCount":12},[],{"trials":2558,"activeCount":12},[],{"intervention":2560,"totalTrials":373,"cells":2561},"Recombinant humanized IL-17A Monoclonal Antibody（JS005）",{"EARLY_PHASE1":2562,"PHASE1":2564,"PHASE2":2566,"PHASE3":2579,"PHASE4":2581,"NA":2583},{"trials":2563,"activeCount":12},[],{"trials":2565,"activeCount":12},[],{"trials":2567,"activeCount":12},[2568],{"nctId":2569,"briefTitle":2570,"status":101,"phases":2571,"primaryCompletion":2572,"completion":2573,"start":2574,"enrollment":2575,"conditions":2576,"interventions":2578},"NCT06250062","A Clinical Study of JS005 in Patients With Ankylosing Spondylitis",[85],"2025-02-26","2025-10-08","2024-01-12",261,[2577],"Ankylosing Spondylitis",[2560],{"trials":2580,"activeCount":12},[],{"trials":2582,"activeCount":12},[],{"trials":2584,"activeCount":12},[],{"intervention":1808,"totalTrials":373,"cells":2586},{"EARLY_PHASE1":2587,"PHASE1":2589,"PHASE2":2591,"PHASE3":2597,"PHASE4":2599,"NA":2601},{"trials":2588,"activeCount":12},[],{"trials":2590,"activeCount":12},[],{"trials":2592,"activeCount":12},[2593],{"nctId":1798,"briefTitle":1799,"status":125,"phases":2594,"primaryCompletion":1801,"completion":1802,"start":1803,"enrollment":1804,"conditions":2595,"interventions":2596},[84,85],[1806],[1748,1808],{"trials":2598,"activeCount":12},[],{"trials":2600,"activeCount":12},[],{"trials":2602,"activeCount":12},[],{"intervention":109,"totalTrials":30,"cells":2604},{"EARLY_PHASE1":2605,"PHASE1":2607,"PHASE2":2624,"PHASE3":2626,"PHASE4":2628,"NA":2630},{"trials":2606,"activeCount":12},[],{"trials":2608,"activeCount":12},[2609,2613],{"nctId":99,"briefTitle":100,"status":101,"phases":2610,"primaryCompletion":103,"completion":104,"start":105,"enrollment":106,"conditions":2611,"interventions":2612},[84],[32],[109,91],{"nctId":2614,"briefTitle":2615,"status":113,"phases":2616,"primaryCompletion":2617,"completion":2617,"start":2618,"enrollment":2619,"conditions":2620,"interventions":2622},"NCT05657418","A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced Pancreatic Cancer",[84],"2025-01-04","2022-03-29",8,[2621],"Advanced Pancreatic Cancer",[109,2623],"JS107 combination with Toripalimab",{"trials":2625,"activeCount":12},[],{"trials":2627,"activeCount":12},[],{"trials":2629,"activeCount":12},[],{"trials":2631,"activeCount":12},[],{"intervention":121,"totalTrials":373,"cells":2633},{"EARLY_PHASE1":2634,"PHASE1":2636,"PHASE2":2642,"PHASE3":2644,"PHASE4":2646,"NA":2648},{"trials":2635,"activeCount":12},[],{"trials":2637,"activeCount":12},[2638],{"nctId":111,"briefTitle":112,"status":113,"phases":2639,"primaryCompletion":115,"completion":115,"start":116,"enrollment":117,"conditions":2640,"interventions":2641},[84],[119],[121,91],{"trials":2643,"activeCount":12},[],{"trials":2645,"activeCount":12},[],{"trials":2647,"activeCount":12},[],{"trials":2649,"activeCount":12},[],{"intervention":2651,"totalTrials":373,"cells":2652},"JS201",{"EARLY_PHASE1":2653,"PHASE1":2655,"PHASE2":2667,"PHASE3":2669,"PHASE4":2671,"NA":2673},{"trials":2654,"activeCount":12},[],{"trials":2656,"activeCount":12},[2657],{"nctId":2658,"briefTitle":2659,"status":101,"phases":2660,"primaryCompletion":2661,"completion":2661,"start":2662,"enrollment":2663,"conditions":2664,"interventions":2666},"NCT04956926","Clinical Study of JS201 in Patients With Advanced Malignant Tumors",[84],"2023-07-07","2021-07-29",244,[2665],"Patients With Advanced Malignant Tumors",[2651],{"trials":2668,"activeCount":12},[],{"trials":2670,"activeCount":12},[],{"trials":2672,"activeCount":12},[],{"trials":2674,"activeCount":12},[],{"intervention":2676,"totalTrials":373,"cells":2677},"JS001+IMP4297",{"EARLY_PHASE1":2678,"PHASE1":2680,"PHASE2":2691,"PHASE3":2693,"PHASE4":2695,"NA":2697},{"trials":2679,"activeCount":12},[],{"trials":2681,"activeCount":12},[2682],{"nctId":2683,"briefTitle":2684,"status":137,"phases":2685,"primaryCompletion":2686,"completion":2687,"start":2618,"enrollment":12,"conditions":2688,"interventions":2690},"NCT05262842","JS001+IMP4297 in Patients With Advanced Cancer",[84],"2024-04-06","2024-06-06",[2689],"Advanced Cancer",[2676],{"trials":2692,"activeCount":12},[],{"trials":2694,"activeCount":12},[],{"trials":2696,"activeCount":12},[],{"trials":2698,"activeCount":12},[],{"intervention":146,"totalTrials":373,"cells":2700},{"EARLY_PHASE1":2701,"PHASE1":2703,"PHASE2":2709,"PHASE3":2711,"PHASE4":2713,"NA":2715},{"trials":2702,"activeCount":12},[],{"trials":2704,"activeCount":12},[2705],{"nctId":135,"briefTitle":136,"status":137,"phases":2706,"primaryCompletion":139,"completion":140,"start":141,"enrollment":12,"conditions":2707,"interventions":2708},[84],[143,144],[146,91],{"trials":2710,"activeCount":12},[],{"trials":2712,"activeCount":12},[],{"trials":2714,"activeCount":12},[],{"trials":2716,"activeCount":12},[],{"intervention":2718,"totalTrials":373,"cells":2719},"JS006 as Monotherapy",{"EARLY_PHASE1":2720,"PHASE1":2722,"PHASE2":2735,"PHASE3":2737,"PHASE4":2739,"NA":2741},{"trials":2721,"activeCount":12},[],{"trials":2723,"activeCount":12},[2724],{"nctId":2725,"briefTitle":2726,"status":101,"phases":2727,"primaryCompletion":2728,"completion":460,"start":2729,"enrollment":2730,"conditions":2731,"interventions":2733},"NCT05061628","The Recombinant Humanized Anti-TIGIT Monoclonal Antibody (JS006) Monotherapy and in Combination With Toripalimab in Patients With Advanced Tumor",[84],"2023-08-14","2021-04-21",176,[2732],"Advanced Tumors",[2718,2734],"JS006 in combination with Toripalimab",{"trials":2736,"activeCount":12},[],{"trials":2738,"activeCount":12},[],{"trials":2740,"activeCount":12},[],{"trials":2742,"activeCount":12},[],{"intervention":2734,"totalTrials":373,"cells":2744},{"EARLY_PHASE1":2745,"PHASE1":2747,"PHASE2":2753,"PHASE3":2755,"PHASE4":2757,"NA":2759},{"trials":2746,"activeCount":12},[],{"trials":2748,"activeCount":12},[2749],{"nctId":2725,"briefTitle":2726,"status":101,"phases":2750,"primaryCompletion":2728,"completion":460,"start":2729,"enrollment":2730,"conditions":2751,"interventions":2752},[84],[2732],[2718,2734],{"trials":2754,"activeCount":12},[],{"trials":2756,"activeCount":12},[],{"trials":2758,"activeCount":12},[],{"trials":2760,"activeCount":12},[],{"intervention":2762,"totalTrials":373,"cells":2763},"Drug: JS004, Recombinant humanized IgG4κ monoclonal antibody specific to BTLA for injection Intravenous",{"EARLY_PHASE1":2764,"PHASE1":2766,"PHASE2":2777,"PHASE3":2779,"PHASE4":2781,"NA":2783},{"trials":2765,"activeCount":12},[],{"trials":2767,"activeCount":12},[2768],{"nctId":2769,"briefTitle":2770,"status":125,"phases":2771,"primaryCompletion":2772,"completion":2772,"start":2773,"enrollment":2774,"conditions":2775,"interventions":2776},"NCT04278859","Safety, Tolerability and Pharmacokinetics of a Recombinant Humanized mAb Specific to B-and T-Lymphocyte Attenuator (BTLA) for Injection in Subjects With Advanced Malignancies",[84],"2023-07-13","2020-04-28",47,[165],[2762],{"trials":2778,"activeCount":12},[],{"trials":2780,"activeCount":12},[],{"trials":2782,"activeCount":12},[],{"trials":2784,"activeCount":12},[],{"intervention":2786,"totalTrials":373,"cells":2787},"JS026\u002Fplacebo",{"EARLY_PHASE1":2788,"PHASE1":2790,"PHASE2":2802,"PHASE3":2804,"PHASE4":2806,"NA":2808},{"trials":2789,"activeCount":12},[],{"trials":2791,"activeCount":12},[2792],{"nctId":2793,"briefTitle":2794,"status":125,"phases":2795,"primaryCompletion":2796,"completion":2796,"start":2797,"enrollment":2798,"conditions":2799,"interventions":2800},"NCT05167279","A Study of JS026 and JS026 Together With JS016 for Treatment of COVID-19",[84],"2022-12-08","2021-12-16",48,[2375],[2786,2801],"JS016\u002Fplacebo",{"trials":2803,"activeCount":12},[],{"trials":2805,"activeCount":12},[],{"trials":2807,"activeCount":12},[],{"trials":2809,"activeCount":12},[],{"intervention":2801,"totalTrials":373,"cells":2811},{"EARLY_PHASE1":2812,"PHASE1":2814,"PHASE2":2820,"PHASE3":2822,"PHASE4":2824,"NA":2826},{"trials":2813,"activeCount":12},[],{"trials":2815,"activeCount":12},[2816],{"nctId":2793,"briefTitle":2794,"status":125,"phases":2817,"primaryCompletion":2796,"completion":2796,"start":2797,"enrollment":2798,"conditions":2818,"interventions":2819},[84],[2375],[2786,2801],{"trials":2821,"activeCount":12},[],{"trials":2823,"activeCount":12},[],{"trials":2825,"activeCount":12},[],{"trials":2827,"activeCount":12},[],{"intervention":2829,"totalTrials":373,"cells":2830},"JS012",{"EARLY_PHASE1":2831,"PHASE1":2833,"PHASE2":2845,"PHASE3":2847,"PHASE4":2849,"NA":2851},{"trials":2832,"activeCount":12},[],{"trials":2834,"activeCount":12},[2835],{"nctId":2836,"briefTitle":2837,"status":113,"phases":2838,"primaryCompletion":2839,"completion":2839,"start":2840,"enrollment":19,"conditions":2841,"interventions":2843},"NCT05388279","A Clinical Study to Evaluate the Safety and Tolerability of JS012 in Advanced or Metastatic Solid Tumors",[84],"2022-09-19","2022-04-28",[2842],"Advanced or Metastatic Solid Tumors",[2829,2844],"JS012 combine with chemotherapy",{"trials":2846,"activeCount":12},[],{"trials":2848,"activeCount":12},[],{"trials":2850,"activeCount":12},[],{"trials":2852,"activeCount":12},[],{"intervention":2844,"totalTrials":373,"cells":2854},{"EARLY_PHASE1":2855,"PHASE1":2857,"PHASE2":2863,"PHASE3":2865,"PHASE4":2867,"NA":2869},{"trials":2856,"activeCount":12},[],{"trials":2858,"activeCount":12},[2859],{"nctId":2836,"briefTitle":2837,"status":113,"phases":2860,"primaryCompletion":2839,"completion":2839,"start":2840,"enrollment":19,"conditions":2861,"interventions":2862},[84],[2842],[2829,2844],{"trials":2864,"activeCount":12},[],{"trials":2866,"activeCount":12},[],{"trials":2868,"activeCount":12},[],{"trials":2870,"activeCount":12},[],{"intervention":2872,"totalTrials":373,"cells":2873},"JS009 as a monotherapy and JS009 as a Triple Combination Therapy in Combination with Toripalimab and JS006",{"EARLY_PHASE1":2874,"PHASE1":2876,"PHASE2":2887,"PHASE3":2889,"PHASE4":2891,"NA":2893},{"trials":2875,"activeCount":12},[],{"trials":2877,"activeCount":12},[2878],{"nctId":2879,"briefTitle":2880,"status":137,"phases":2881,"primaryCompletion":2882,"completion":2883,"start":232,"enrollment":12,"conditions":2884,"interventions":2886},"NCT05650203","A Study of JS009 Monotherapy and JS009 as a Triple Combination Therapy in Patients With Advanced Malignancies",[84],"2025-10-25","2026-12-31",[2885],"Primary Condition: Advanced Tumors",[2872],{"trials":2888,"activeCount":12},[],{"trials":2890,"activeCount":12},[],{"trials":2892,"activeCount":12},[],{"trials":2894,"activeCount":12},[],{"intervention":2250,"totalTrials":373,"cells":2896},{"EARLY_PHASE1":2897,"PHASE1":2899,"PHASE2":2905,"PHASE3":2907,"PHASE4":2909,"NA":2911},{"trials":2898,"activeCount":12},[],{"trials":2900,"activeCount":12},[2901],{"nctId":2241,"briefTitle":2242,"status":125,"phases":2902,"primaryCompletion":2244,"completion":2244,"start":2245,"enrollment":2246,"conditions":2903,"interventions":2904},[84],[2248],[2234,2250],{"trials":2906,"activeCount":12},[],{"trials":2908,"activeCount":12},[],{"trials":2910,"activeCount":12},[],{"trials":2912,"activeCount":12},[],{"intervention":2914,"totalTrials":373,"cells":2915},"JS001(Toripalimab)+JS002",{"EARLY_PHASE1":2916,"PHASE1":2918,"PHASE2":2927,"PHASE3":2929,"PHASE4":2931,"NA":2933},{"trials":2917,"activeCount":12},[],{"trials":2919,"activeCount":12},[2920],{"nctId":2921,"briefTitle":2922,"status":113,"phases":2923,"primaryCompletion":2924,"completion":2924,"start":651,"enrollment":846,"conditions":2925,"interventions":2926},"NCT05128539","A Study Explore JS001+JS002 in Patients With Advanced Cancer",[84],"2023-11-10",[2689],[2914],{"trials":2928,"activeCount":12},[],{"trials":2930,"activeCount":12},[],{"trials":2932,"activeCount":12},[],{"trials":2934,"activeCount":12},[],{"intervention":2936,"totalTrials":373,"cells":2937},"JS401",{"EARLY_PHASE1":2938,"PHASE1":2940,"PHASE2":2953,"PHASE3":2955,"PHASE4":2957,"NA":2959},{"trials":2939,"activeCount":12},[],{"trials":2941,"activeCount":12},[2942],{"nctId":2943,"briefTitle":2944,"status":101,"phases":2945,"primaryCompletion":2946,"completion":2947,"start":2948,"enrollment":2949,"conditions":2950,"interventions":2952},"NCT06041165","A Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of JS401",[84],"2024-06-29","2024-09-21","2023-08-31",44,[2951],"Hyperlipidemia",[2936],{"trials":2954,"activeCount":12},[],{"trials":2956,"activeCount":12},[],{"trials":2958,"activeCount":12},[],{"trials":2960,"activeCount":12},[],{"intervention":2962,"totalTrials":373,"cells":2963},"JS108",{"EARLY_PHASE1":2964,"PHASE1":2966,"PHASE2":2976,"PHASE3":2978,"PHASE4":2980,"NA":2982},{"trials":2965,"activeCount":12},[],{"trials":2967,"activeCount":12},[2968],{"nctId":2969,"briefTitle":2970,"status":113,"phases":2971,"primaryCompletion":2972,"completion":2972,"start":2973,"enrollment":9,"conditions":2974,"interventions":2975},"NCT04601285","A Phase I Study of JS108 in Patients With Advanced Solid Tumors",[84],"2023-06-14","2020-10-28",[32],[2962],{"trials":2977,"activeCount":12},[],{"trials":2979,"activeCount":12},[],{"trials":2981,"activeCount":12},[],{"trials":2983,"activeCount":12},[],{"intervention":2985,"totalTrials":373,"cells":2986},"JS016",{"EARLY_PHASE1":2987,"PHASE1":2989,"PHASE2":3000,"PHASE3":3002,"PHASE4":3004,"NA":3006},{"trials":2988,"activeCount":12},[],{"trials":2990,"activeCount":12},[2991],{"nctId":2992,"briefTitle":2993,"status":101,"phases":2994,"primaryCompletion":2995,"completion":2995,"start":2996,"enrollment":196,"conditions":2997,"interventions":2999},"NCT04441918","Tolerability,Safety,Pharmacokinetic Profile and Immunogenicity of a Recombinant Humanized Anti-SARS-CoV-2 Monoclonal Antibody (JS016) for Injection in Chinese Health Subjects",[84],"2020-12-11","2020-06-05",[2998],"COVID-19; and High Infection Risk of SARS-CoV-2",[2985],{"trials":3001,"activeCount":12},[],{"trials":3003,"activeCount":12},[],{"trials":3005,"activeCount":12},[],{"trials":3007,"activeCount":12},[],{"intervention":3009,"totalTrials":373,"cells":3010},"Toripalimab injection(subcutaneous)\u002FJS001sc",{"EARLY_PHASE1":3011,"PHASE1":3013,"PHASE2":3026,"PHASE3":3028,"PHASE4":3030,"NA":3032},{"trials":3012,"activeCount":12},[],{"trials":3014,"activeCount":12},[3015],{"nctId":3016,"briefTitle":3017,"status":101,"phases":3018,"primaryCompletion":3019,"completion":3020,"start":3021,"enrollment":2158,"conditions":3022,"interventions":3024},"NCT05751486","A Clinical Study to Evaluate the Safety and Tolerability of JS001sc in Advanced Nasopharyngeal Carcinoma",[84],"2023-12-30","2025-12-30","2022-10-21",[3023],"Advanced Nasopharyngeal Carcinoma",[3009,3009,3025,3009],"Toripalimab \u002FJS001",{"trials":3027,"activeCount":12},[],{"trials":3029,"activeCount":12},[],{"trials":3031,"activeCount":12},[],{"trials":3033,"activeCount":12},[],{"intervention":3025,"totalTrials":373,"cells":3035},{"EARLY_PHASE1":3036,"PHASE1":3038,"PHASE2":3044,"PHASE3":3046,"PHASE4":3048,"NA":3050},{"trials":3037,"activeCount":12},[],{"trials":3039,"activeCount":12},[3040],{"nctId":3016,"briefTitle":3017,"status":101,"phases":3041,"primaryCompletion":3019,"completion":3020,"start":3021,"enrollment":2158,"conditions":3042,"interventions":3043},[84],[3023],[3009,3009,3025,3009],{"trials":3045,"activeCount":12},[],{"trials":3047,"activeCount":12},[],{"trials":3049,"activeCount":12},[],{"trials":3051,"activeCount":12},[],{"intervention":3053,"totalTrials":373,"cells":3054},"JS010",{"EARLY_PHASE1":3055,"PHASE1":3057,"PHASE2":3067,"PHASE3":3069,"PHASE4":3071,"NA":3073},{"trials":3056,"activeCount":12},[],{"trials":3058,"activeCount":12},[3059],{"nctId":3060,"briefTitle":3061,"status":101,"phases":3062,"primaryCompletion":2946,"completion":2947,"start":3063,"enrollment":2798,"conditions":3064,"interventions":3066},"NCT06158737","A Clinical Trial Evaluated the Safety and Tolerability, Pharmacokinetic and Pharmacodynamics Profile, and Immunogenicity of a Single Dose of JS010 Injection in Healthy Subjects",[84],"2023-05-09",[3065],"Migraine",[3053],{"trials":3068,"activeCount":12},[],{"trials":3070,"activeCount":12},[],{"trials":3072,"activeCount":12},[],{"trials":3074,"activeCount":12},[],{"intervention":3076,"totalTrials":373,"cells":3077},"JS004, a recombinant humanized, IgG4κ monoclonal antibody (mAb) specific to B- and T-lymphocyte attenuator (BTLA); Toripalimab",{"EARLY_PHASE1":3078,"PHASE1":3080,"PHASE2":3094,"PHASE3":3096,"PHASE4":3098,"NA":3100},{"trials":3079,"activeCount":12},[],{"trials":3081,"activeCount":12},[3082],{"nctId":3083,"briefTitle":3084,"status":101,"phases":3085,"primaryCompletion":3086,"completion":3087,"start":3088,"enrollment":3089,"conditions":3090,"interventions":3093},"NCT04773951","A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of JS004 in Advanced Solid Tumors",[84],"2024-02-29","2024-08-31","2021-04-12",156,[25,3091,3092],"Renal Carcinoma","Urothelial Carcinoma",[3076],{"trials":3095,"activeCount":12},[],{"trials":3097,"activeCount":12},[],{"trials":3099,"activeCount":12},[],{"trials":3101,"activeCount":12},[],{"intervention":2623,"totalTrials":373,"cells":3103},{"EARLY_PHASE1":3104,"PHASE1":3106,"PHASE2":3112,"PHASE3":3114,"PHASE4":3116,"NA":3118},{"trials":3105,"activeCount":12},[],{"trials":3107,"activeCount":12},[3108],{"nctId":2614,"briefTitle":2615,"status":113,"phases":3109,"primaryCompletion":2617,"completion":2617,"start":2618,"enrollment":2619,"conditions":3110,"interventions":3111},[84],[2621],[109,2623],{"trials":3113,"activeCount":12},[],{"trials":3115,"activeCount":12},[],{"trials":3117,"activeCount":12},[],{"trials":3119,"activeCount":12},[]]